

DESCRIPTION

RGMa BINDING PROTEIN AND USE THEREOF

5 TECHNICAL FIELD

[0001]

The present invention relates to an RGMa-binding protein and a use thereof.

BACKGROUND ART

10 [0002]

RGM (repulsive guidance molecule), which is a GPI-anchored membrane protein with a molecular weight of about 33 kDa, has been initially identified as an axon guidance molecule in the visual system (see Non-Patent Document 1). The RGM family includes three members called RGMa, RGMb and RGMc. Among
15 them, RGMa is re-expressed after central nervous system injury in adult humans and rats as well as at developmental stage, and RGMa inhibition in rat accelerates neurite outgrowth after spinal cord injury and promotes functional recovery (see Non-Patent Document 2). Thus, RGMa is thought to be a neurite inhibitor after central nervous system injury.

20 [0003]

RGMa also has been reported to have effects in the immune system. RGMa is expressed on dendritic cells and acts on T cells, thereby enhancing adhesion of T cells to ICAM-1 and fibronectin and inducing cytokine production (Patent Document 4). In a mouse model of multiple sclerosis, administration of anti-RGMa antibody
25 suppresses symptoms due to encephalomyelitis and also shows effects of suppressing onset and relapse. It is thought that anti-RGMa antibody binds to RGMa expressed on dendritic cells to inhibit the activation of T cells, thereby exerting effects on multiple sclerosis.

[0004]

The signal transduction mechanism of RGMa is also being elucidated, and neogenin protein has been reported as an RGMa receptor (Patent Document 3).

Neogenin is a single-transmembrane protein expressed on neurons and T cells.

5 RGMa binds to neogenin on a cell membrane to induce intracellular RhoA activation and Ras inactivation, thereby providing a neurite outgrowth inhibitory effect. Meanwhile, neogenin is known to cause apoptosis in the absence of RGMa binding in a developing chicken brain (Matsunaga et al., Dev.Growth Differ.46, 481, 2004). Thus, the RGMa/neogenin pathway is thought to have two conflicting effects
10 of promoting neuronal survival, which is a favorable effect for nerve regeneration, and of inhibiting neurite outgrowth, a negative effect.

[0005]

As a pharmaceutical agent targeting RGM, Patent Document 1 discloses an axon regeneration promoting agent containing an anti-RGM neutralizing antibody as
15 an active ingredient. Patent Documents 2 and 3 disclose a therapeutic agent for mechanical damage to brain and spinal cord, an anti-RGM antibody that regulates the binding of RGM to its receptor neogenin. Patent Document 4 discloses medical uses of anti-RGM antibody such as for multiple sclerosis. Patent Document 5 discloses therapeutic uses of anti-RGM antibody for diseases including multiple sclerosis,
20 mammalian brain injury, spinal cord injury, apoplexy, neurodegenerative disease and schizophrenia. Furthermore, Patent Document 6 discloses therapeutic uses of RGM modulators such as anti-RGM antibody for spinal cord injury and multiple sclerosis, and Non-Patent Document 3 discloses a therapeutic use for progressive multiple sclerosis.

25

PRIOR ART DOCUMENTS

PATENT DOCUMENTS

[0006]

Patent Document 1: WO2005/087268

Patent Document 2: Japanese Translated PCT Patent Application Laid-open No.
2010-537655

Patent Document 3: Japanese Translated PCT Patent Application Laid-open No.
5 2009-510002

Patent Document 4: WO2011/071059

Patent Document 5: Japanese Translated PCT Patent Application Laid-open No.
2011-512806

Patent Document 6: Japanese Translated PCT Patent Application Laid-open No.
10 2004-525875

NON-PATENT DOCUMENTS

[0007]

Non-Patent Document 1: Neuron 5, 735-743 (1990)

15 Non-Patent Document 2: J. Cell Biol. 173, 47-58 (2006)

Non-Patent Document 3: Cell Reports 10, 1-12 (2015)

SUMMARY OF THE INVENTION

TECHNICAL PROBLEM

20 [0008]

Therapeutic uses of anti-RGMA antibody against neurological and immunological diseases are disclosed as described above, but conventional antibodies have problems such as insufficient activity, possibility of impairing intrinsic functions of RGMA, and side effects. In particular, conventional antibodies may inhibit binding between RGMA and neogenin, thereby also inhibiting favorable effects such as apoptosis suppression exerted by neogenin bound to RGMA.

Thus, an object of the present invention is to provide an RGMA-binding protein which does not inhibit RGMA/neogenin interaction but neutralizes the neurite

outgrowth inhibiting activity of RGMa.

SOLUTION TO PROBLEM

[0009]

5 The inventors of the present invention intensively studied in order to solve the above problems. As a result, the present inventors have succeeded in obtaining an RGMa-binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, and have found that the RGMa-binding protein can be used as a medicine for neurological or
10 immunological diseases, thereby completing the present invention.

[0010]

The present invention is as follows.

[1] An isolated RGMa-binding protein, which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of
15 RGMa.

[2] The RGMa-binding protein described in [1], which binds to human, rat and/or mouse RGMa.

[3] The RGMa-binding protein described in [1] or [2], which binds to peptides of EEVVNAVEDWDSQG (SEQ ID NO: 26 in Sequence Listing),
20 NQQIDFQAFHTNAE (SEQ ID NO: 27 in Sequence Listing), PTAPETFPYET (SEQ ID NO: 28 in Sequence Listing), and/or KLPVEDLYYQA (SEQ ID NO: 29 in Sequence Listing).

[4] The RGMa-binding protein described in any one of [1] to [3], which binds to peptides of SEQ ID NOS: 26 and 27 in Sequence Listing.

25 [5] The RGMa-binding protein described in any one of [1] to [4], which binds to peptides of SEQ ID NOS: 26, 27 and 28 in Sequence Listing.

[6] The RGMa-binding protein described in any one of [1] to [4], which binds to peptides of SEQ ID NOS: 26, 27 and 29 in Sequence Listing.

- [7] The RGMa-binding protein described in any one of [1] to [6], wherein the RGMa-binding protein is a human antibody, a humanized antibody or a chimeric antibody, or an antigen-binding fragment thereof.
- [8] A nucleic acid molecule coding for the protein portion of the RGMa-binding
 5 protein described in any one of [1] to [7].
- [9] A recombinant vector comprising the nucleic acid molecule described in [8].
- [10] A host cell containing the recombinant vector described in [9].
- [11] A method for producing the RGMa-binding protein described in [1] to [7], the method comprising a step of culturing the host cell described in [10].
- 10 [12] A pharmaceutical composition comprising the RGMa-binding protein described in any one of [1] to [7].
- [13] The pharmaceutical composition described in [12] for use in preventing, treating, or preventing the relapse of neurological or immunological diseases.
- [14] The pharmaceutical composition described in [13], wherein the neurological
 15 diseases are selected from the group consisting of amyotrophic lateral sclerosis, brachial plexus injury, brain damage (including traumatic brain injury), cerebral palsy, Guillain-Barre syndrome, cerebral leukodystrophy, multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, post-polio
 20 syndrome, spina bifida, spinal cord injury, spinal muscular atrophy, spinal neoplasm, transverse myelitis, dementia (including senile dementia, mild cognitive impairment, Alzheimer's disease, dementia associated with Alzheimer's disease), Huntington's disease, tardive dyskinesia, mania, Parkinson's disease, Steele-Richardson syndrome, Down's syndrome, myasthenia gravis, neurotrauma (including optic nerve trauma),
 25 vascular amyloidosis, cerebral hemorrhage associated with amyloidosis, brain infarction, cerebritis, acute confusional state, glaucoma, schizophrenia and retinal nerve fiber layer degeneration (including diabetic retinopathy, ischemic optic neuropathy, X-linked retinoschisis, drug-induced optic neuropathy, retinal dystrophy,

age-related macular degeneration, eye diseases characterized by optic disc drusen, eye diseases characterized by genetic determinant for photoreceptor degeneration, autosomal recessive cone-rod dystrophy, mitochondrial disorder associated with optic neuropathy).

- 5 [15] The pharmaceutical composition described in [13], wherein the immunological diseases are selected from the group consisting of multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, psoriasis, arthritis (including rheumatoid arthritis, osteoarthritis, psoriatic arthritis), Guillain-
10 Barre syndrome, neuro-Behcet disease, pernicious anemia, type I (insulin-dependent) diabetes mellitus, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), Sjogren's syndrome, Goodpasture's syndrome, Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, asthma, pollinosis, atopic dermatitis, glomerulonephritis, myasthenia gravis, Hashimoto's
15 disease, and sarcoidosis.

- [16] The pharmaceutical composition described in [13], wherein the neurological or immunological diseases are selected from the group consisting of spinal cord injury, neurotrauma (including optic nerve trauma) and multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis,
20 secondary progressive multiple sclerosis).

- [17] An isolated anti-RGMA antibody, or an antigen-binding fragment thereof, wherein the amino acid sequence of each of the light chain complementarity determining region 1 (LCDR1), the light chain complementarity determining region 2 (LCDR2), the light chain complementarity determining region 3 (LCDR3), the
25 heavy chain complementarity determining region 1 (HCDR1), the heavy chain complementarity determining region 2 (HCDR2) and the heavy chain complementarity determining region 3 (HCDR3) comprises the following:
LCDR1:RASQDISSYLN (SEQ ID NO: 30 in Sequence Listing)

LCDR2:YTSRLHS (SEQ ID NO: 31 in Sequence Listing)

LCDR3:QQLNTLP (SEQ ID NO: 32 in Sequence Listing)

HCDR1:DAWMD (SEQ ID NO: 33 in Sequence Listing)

HCDR2:EIRSKANNHATYYAESVKG (SEQ ID NO: 34 in Sequence Listing) and

5 HCDR3:RDGAY (SEQ ID NO: 35 in Sequence Listing);

or

LCDR1:RSSQSLVHSNGNTYLH (SEQ ID NO: 36 in Sequence Listing)

LCDR2:KVSNRFS (SEQ ID NO: 37 in Sequence Listing)

LCDR3:SQSTHVP (SEQ ID NO: 38 in Sequence Listing)

10 HCDR1:TSYYWN (SEQ ID NO: 39 in Sequence Listing)

HCDR2:YISYDGTNNYNPSLKN (SEQ ID NO: 40 in Sequence Listing) and

HCDR3:SFG, and

wherein in each of the CDR sequences one or several amino acids may be substituted, deleted, and/or added.

15 [18] The anti-RGMa antibody or an antigen-binding fragment thereof described in [17],

wherein the heavy chain variable region (VH) comprises the following:

VH:

EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAE

20 IRSKANNHATYYAESVKG RFTISRDDSKSIVY LQMNSLRTE DTALYYCTRRD

GAYWGKGTTVTVSS (SEQ ID NO: 41 in Sequence Listing) or an amino acid sequence having an identity of at least 90% with said amino acid sequence; and

wherein the light chainvariable region (VL) comprises the following:

VL:

25 DIQMTQSPSSVSASVGDRVITTCRASQDISSYLNWYQQKPGKAPKLLIYYTSR

LHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGG TKVEM

E (SEQ ID NO: 42 in Sequence Listing) or an amino acid sequence having an identity of at least 90% with said amino acid sequence.

[19] The anti-RGMa antibody or an antigen-binding fragment thereof described in [17] or [18], wherein the anti-RGMa antibody is a humanized antibody.

[20] The anti-RGMa antibody or an antigen-binding fragment thereof described in any one of [17] to [19], wherein the anti-RGMa antibody comprises a constant

5 region of human IgG.

[21] An RGMa-binding protein, which competes with the anti-RGMa antibody described in [17] or [18] for binding to RGMa.

[22] A nucleic acid molecule coding for the protein portion of the anti-RGMa antibody or an antigen-binding fragment thereof described in any one of [17] to [20].

10 [23] The nucleic acid molecule described in [22], wherein the nucleotide sequences coding for the VH and VL amino acid sequences each is a nucleotide sequence comprising:

VH:

gaagtgcagctgggtggaatctggcggcgactgggtgcagcctggcagatccctgagactgtcctgtaccgctccggct
 15 tcaccttctccgacgcctggatggattgggtgcgacaggctcctggcaagggcctggaatgggtggccgagatccggtc
 caaggccaacaaccacgccactactacgccgagctgtgaagggccgggtcaccatctcccgaggacgactccaagtcc
 atcgtgtacctgcagatgaactccctgcggaccgaggacaccgccctgtactactgcaccagaagggacggcgctact
 ggggcaagggcaccacagtgcagtgctctcc (SEQ ID NO: 43 in Sequence Listing), and

VL:

20 gacatccagatgaccagtcctccctcctcctgtgtctgcttccgtggcgacagagtgaccatcacctgtcgggcctccca
 ggacatctcctctactgaactgggtatcagcagaagcccggaagggccccaagctgtgatctactacacctccggc
 tgcactccggcgtgccctctagatttccggctctggctccggcaccgactttaccctgaccatctccagcctgcagcccg
 aggacttcgcctcctacttctgtcagcagctgaacaccctgcctggaccttggcggaggcaccaaggtggaaatggaa
 (SEQ ID NO: 44 in Sequence Listing).

25 [24] A recombinant vector comprising the nucleic acid molecule described in [22] or [23].

[25] A host cell containing the recombinant vector described in [24].

[26] A method for producing the anti-RGMa antibody or an antigen-binding

fragment thereof described in any one of [17] to [20], the method comprising a step of culturing the host cell described in [25].

[27] A pharmaceutical composition comprising the anti-RGMA antibody or an antigen-binding fragment thereof described in any one of [17] to [20].

5 [28] The pharmaceutical composition described in [27] for use in preventing, treating, or preventing the relapse of neurological or immunological diseases.

[29] The pharmaceutical composition described in [28], wherein the neurological diseases are selected from the group consisting of amyotrophic lateral sclerosis, brachial plexus injury, brain damage (including traumatic brain injury), cerebral
10 palsy, Guillain-Barre syndrome, cerebral leukodystrophy, multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, post-polio syndrome, spina bifida, spinal cord injury, spinal muscular atrophy, spinal neoplasm, transverse myelitis, dementia (including senile dementia, mild cognitive impairment,
15 Alzheimer's disease, dementia associated with Alzheimer's disease), Huntington's disease, tardive dyskinesia, mania, Parkinson's disease, Steele-Richardson syndrome, Down's syndrome, myasthenia gravis, neurotrauma (including optic nerve trauma), vascular amyloidosis, cerebral hemorrhage associated with amyloidosis, brain infarction, cerebritis, acute confusional state, glaucoma, schizophrenia and retinal
20 nerve fiber layer degeneration (including diabetic retinopathy, ischemic optic neuropathy, X-linked retinoschisis, drug-induced optic neuropathy, retinal dystrophy, age-related macular degeneration, eye diseases characterized by optic disc drusen, eye diseases characterized by genetic determinant for photoreceptor degeneration, autosomal recessive cone-rod dystrophy, mitochondrial disorder associated with
25 optic neuropathy).

[30] The pharmaceutical composition described in [28], wherein the immunological diseases are selected from the group consisting of multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple

sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, psoriasis, arthritis (including rheumatoid arthritis, osteoarthritis, psoriatic arthritis), Guillain-Barre syndrome, neuro-Behcet disease, pernicious anemia, type I (insulin-dependent) diabetes mellitus, systemic lupus erythematosus (SLE), inflammatory
 5 bowel disease (IBD), Sjogren's syndrome, Goodpasture's syndrome, Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, asthma, pollinosis, atopic dermatitis, glomerulonephritis, myasthenia gravis, Hashimoto's disease, and sarcoidosis.

[31] The pharmaceutical composition described in [28], wherein the neurological
 10 or immunological diseases are selected from the group consisting of spinal cord injury, neurotrauma (including optic nerve trauma) and multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis).

[32] A method for preventing, treating, or preventing the relapse of neurological
 15 or immunological diseases, the method comprising a step of administering a effective dose of the RGMa-binding protein described in any one of [1] to [7] to a subject in need thereof.

[33] A method for preventing, treating, or preventing the relapse of neurological
 20 or immunological diseases, the method comprising a step of administering an effective dose of the anti-RGMa antibody or an antigen-binding fragment thereof described in any one of [17] to [20] to a subject in need thereof.

ADVANTAGEOUS EFFECT OF THE INVENTION

[0011]

25 The RGMa-binding protein of the present invention does not inhibit the interaction between RGMa and neogenin, thereby being able to maintain effects such as apoptosis inhibition on neurons and the like exerted by neogenin bound to RGMa, thus having a strong protective effect on neurons and little concern for side effects

associated with neuron depletion. In addition, the humanized anti-RGMa antibody of the present invention is superior to conventional antibodies in properties such as binding to human RGMa and thermal stability. Therefore, the antibody can be used as a medicine for neurological or immunological diseases which has an excellent efficacy and few side effects.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012]

Fig. 1 shows a result of an RGMa-neogenin binding inhibition assay using an anti-RGMa polyclonal antibody (AF2459), an antibody of comparative example (r5F9), and antibodies of the present invention (r70E4 and 116A3).

Fig. 2 shows a result of an RGMa-BMP2 binding inhibition assay using a control mouse-IgG and antibodies of the present invention (B5.70E4 and B5.116A3).

Fig. 3 shows a result of a thermal stability test for antibodies using an antibody of comparative example (rH5F9), a chimeric antibody of the present invention (r116A3C) and humanized antibodies of the present invention (HE/KA and HA/KC).

Fig. 4 shows a result of a neurite outgrowth assay using the antibodies of the present invention (B5.70E4 (left) and B5.116A3 (right)).

Fig. 5 shows a result of an efficacy test using a control mouse-IgG (mouse IgG2bk), and the antibodies of the present invention (r70E4 and r116A3) and using a rat model of spinal cord injury. Results of efficacy tests in (A) a spinal cord crush model and (B) a spinal cord hemisection model are shown.

Fig. 6 shows a result of an efficacy test for the antibody of the present invention (B5.116A3) using a mouse model of multiple sclerosis induced by a PLP₁₃₉₋₁₅₁ peptide. The left side shows EAE scores, the right side shows changes in body weight, and the top and bottom parts show results when the test antibodies were administered after 7 and 10 days and after 18 and 21 days, respectively.

DESCRIPTION OF THE EMBODIMENTS

[0013]

In order to facilitate understanding of the present invention, the terms used
5 in the present invention will be explained below.

[0014]

RGMa

RGMa is a neurite outgrowth inhibitory protein in the central nervous
system and human RGMa protein is biosynthesized as a precursor protein comprising
10 450 amino acids as shown in SEQ ID NO: 1 in Sequence Listing. The signal peptide
Met 1 to Pro 47 present at the N terminus (which refers to the peptide from the first
methionine residue to the 47th proline residue from the N-terminal side, similarly
described hereafter) is removed, the peptide bond between Asp 168 and Pro 169 is
cleaved, and the C-terminal peptide Arg 423 to Cys 450 is removed and
15 simultaneously a GPI anchor is added to the C-terminal carboxyl group of Gly 422
which has become the C-terminus. A human RGMa protein is expressed on a cell
membrane via the GPI anchor as a mature protein in which the N-terminal domain
(Cys 48 to Asp 168) and the C-terminal domain (Pro 169 to Ala 424) are joined
together by a disulfide bond. A precursor protein of mouse RGMa comprises the
20 amino acid sequence shown in SEQ ID NO: 2 in Sequence Listing and a precursor
protein of rat RGMa comprises the amino acid sequence shown in SEQ ID NO: 3 in
Sequence Listing. Since their C terminal peptides are removed, mature proteins
therefrom have the same amino acid sequences. In the present invention, RGMa may
refer to either a precursor protein, a mature protein or an active fragment thereof, or
25 may be a derivative or variant thereof, as long as it acts via binding to neogenin as
described later. RGMa may be human RGMa or RGMa derived from other
organisms, but human RGMa is preferred.

[0015]

Neogenin

Neogenin is expressed in, for example, central nervous neurons and functions as one of RGMa receptors. As shown in SEQ ID NO: 10 in Sequence Listing, the human neogenin protein comprises 1461 amino acids and is expressed as

5 a mature membrane protein after removal of the signal peptide Met 1 to Ala 33. In the present invention, neogenin may refer to either a precursor protein, a mature protein or an RGMa-binding fragment, or may be a derivative or variant thereof, as long as it binds to RGMa. Neogenin may be human neogenin or neogenin derived from other organisms, but human neogenin is preferred.

10 [0016]

Neutralization

The term "neutralization" as used herein refers to an action through which binding to a target of interest and inhibition of any function of the target can occur. In other words, the phrase "neutralizing the neurite outgrowth inhibitory activity of

15 RGMa" means that an RGMa binding protein binds to RGMa, thereby inhibiting the neurite outgrowth inhibitory activity of RGMa. Neurite outgrowth inhibitory activity can be assessed by one or more of several in vitro or in vivo assays known in the art, and can be assessed by, for example, the neurite outgrowth inhibition assay described herein.

20 [0017]

Isolated

The term "isolated" such as in isolated RGMa-binding protein means being identified, and separated and/or recovered from components in its natural state. Impurities in the natural state are substances that can interfere with the diagnostic or

25 therapeutic use of the antibody, including enzymes, hormones and other proteinous or nonproteinous solutes. Generally, isolation of RGMa-binding protein or the like can be achieved by at least one purification step. The RGMa binding protein purified by at least one purification step can be referred to as "isolated RGMa-binding

protein".

[0018]

RGMa-Binding Protein

As used herein, the term "RGMa-binding protein" refers to a molecule
 5 comprising a protein that binds to RGMa. Examples of the RGMa-binding proteins
 include anti-RGMa antibodies and antigen-binding fragments thereof; RGMa-
 binding scaffold proteins; soluble RGMa receptor proteins such as extracellular
 domain of Neogenin; and fusion proteins thereof. The term "RGMa-binding scaffold
 protein" refers to a protein that realizes the function of binding to RGMa by
 10 introduction of mutations into the Kunitz domain of a serine protease inhibitor, the
 extracellular domain of human fibronectin, ankyrin, lipocalin or the like. The term
 "fusion protein" refers to RGMa-binding proteins bound chemically or genetically to
 function molecules other than the RGMa-binding protein of the present application
 such as nonpeptidic polymers such as polyethylene glycol (PEG), radioactive
 15 substances, toxins, low molecular weight compounds, cytokines, growth factors (e.g.,
 TGF- β , NGF, neurotrophin), albumin, enzymes, and other antibodies.

[0019]

Human Antibody

The term "human antibody" refers to an antibody in which light and heavy
 20 chains are both derived from human immunoglobulin. Depending on the difference
 in constant regions of heavy chains, human antibodies include IgG having γ -heavy
 chains (including IgG1, IgG2, IgG3 and IgG4), IgM having μ -heavy chains, IgA
 having α -heavy chains (including IgA1 and IgA2), IgD having δ -heavy chains, or
 IgE having ϵ -heavy chains. Light chains, in principle, comprise either κ chains or λ
 25 chains.

[0020]

Humanized Antibody

The term "humanized antibody" refers to an antibody comprising variable

regions comprising complementarity determining regions of an antibody derived from a nonhuman animal and framework regions derived from a human antibody, and constant regions derived from a human antibody.

[0021]

5 *Chimeric Antibody*

The term "chimeric antibody" refers to an antibody in which the light chain, the heavy chain, or both comprises a non-human derived variable region and a human derived constant region.

[0022]

10 *Anti-RGMa antibody*

As used herein, the term "anti-RGMa antibody" refers to immunoglobulin molecules which bind to RGMa, or modified molecules thereof. Modified molecules include multispecific antibodies, chimeric antibodies, humanized antibodies, functionally modified antibodies, and conjugated antibodies.

15 [0023]

Multispecific Antibody

The term "multispecific antibody" refers to an asymmetric antibody comprising two or more independent antigen recognition sites having two or more different antigen specificities, including bispecific antibody having two antigen specificities and trispecific antibody having three antigen specificities.

20

[0024]

Functionally Modified Antibody

As used herein, the term "functionally modified antibody" refers to an antibody in which functions other than the antigen binding function of the antibody, including cell killing function, complement activating function and serum half-life extending function, are modified by mainly modifying the amino acid or sugar chain of the Fc region of the antibody.

25

[0025]

Conjugated Antibody

As used herein, the term "conjugated antibody" refer to an antibody bound chemically or genetically to function molecules other than antibody such as nonpeptidic polymers such as polyethylene glycol (PEG), radioactive substances,
 5 toxins, low molecular weight compounds, cytokines, growth factors (e.g., TGF- β , NGF, neurotrophin), albumin, and enzymes.

[0026]

Antigen-Binding Fragment

As used herein, the term "antigen-binding fragment" refers to a protein
 10 which comprises a part of an antibody and can bind to an antigen. Examples of the antigen-binding fragment include F(ab')₂, Fab', Fab, Fv (variable fragment of antibody), disulfide-linked Fv, single-chain antibody (scFv), and polymers thereof. In addition, the antigen-binding fragment includes conjugated antigen-binding
 15 fragments bound chemically or genetically to function molecules other than the anti-RGMa antibody in the present application such as nonpeptidic polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, growth factors (e.g., TGF- β , NGF, neurotrophin), albumin, enzymes, and other antibodies.

[0027]

20 Complementarity Determining Region

The term "complementarity determining region (CDR)" refers to a region forming an antigen binding site in a variable region of an immunoglobulin molecule, which is also called a hypervariable region, and particularly refers to a portion in which the amino acid sequence changes greatly for each immunoglobulin molecule.
 25 As CDR, light and heavy chains each have three CDRs (LCDR1, LCDR2, LCDR3, and HCDR1, HCDR2, HCDR3). In the present application, CDRs of an immunoglobulin molecule are determined according to the Kabat numbering system (Kabat et al., 1987, Sequences of Proteins of Immunological Interest, US Department

of Health and Human Services, NIH, USA).

[0028]

Percent (%) Identity of Amino Acid Sequence

"Percent (%) identity" with respect to the identified reference polypeptide
5 sequence, such as variable region, is defined as the percentage of amino acid residues
in a candidate sequence that are identical to the amino acid residues of a particular
reference polypeptide sequence, after arranging the sequences and introducing gaps
as necessary in order to obtain maximal % identity and assuming that no
conservative substitutions are considered part of the sequence identity. Alignment
10 for purposes of determining % identity can be accomplished by using various
methods within the skill of the art, for example, using publicly available computer
software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software.
Those skilled in the art can determine appropriate parameters for aligning sequences,
including any algorithms necessary to achieve maximal alignment over the full
15 length of the sequences being compared. However, for purposes herein, % identity
values are obtained by using the sequence comparison computer program BLAST in
pairwise alignments.

In situations where BLAST is used for amino acid sequence comparisons,
the % identity of a given amino acid sequence A to a given amino acid sequence B is
20 calculated as follows:

100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches
by the sequence alignment program Blast in that program's alignment of A and B,
and where Y is the total number of amino acid residues in B. It will be appreciated
25 that if the length of amino acid sequence A is different from the length of amino acid
sequence B, the % identity of A to B will be different from the % identity of B to A.
Unless stated otherwise, all % identity values herein are obtained using the BLAST
computer program as shown in the immediately preceding paragraph.

[0029]

Competing

As used herein, the term "competing" with the anti-RGMa antibody of the present invention means that, as measured by the surface plasmon resonance (SPR) described herein, the binding between the anti-RGMa antibody of the present invention and RGMa is decreased with a significant difference due to the presence of said anti-RGMa antibody or an antigen-binding fragment thereof.

[0030]

The present invention will be described in detail below.

10 *RGMa-Binding Protein*

The RGMa-binding protein of the present invention is an isolated RGMa-binding protein, which does not inhibit binding between RGMa and neogenin but neutralizes neurite outgrowth inhibiting activity of RGMa.

[0031]

15 Preferably, RGMa proteins are RGMa proteins derived from mammals. For example, human RGMa proteins include a protein having the amino acid sequence of SEQ ID NO: 1 in Sequence Listing, mouse RGMa proteins include a protein having the amino acid sequence of SEQ ID NO: 2 in Sequence Listing, and rat RGMa proteins include a protein having the amino acid sequence of SEQ ID NO: 20 3 in Sequence Listing. A polypeptide comprising an amino acid sequence wherein one or several (preferably 1 to 20, more preferably 1 to 10, still more preferably 1 to 5) amino acids in these sequences are substituted, deleted, inserted and/or added and having substantially the same activity as RGMa protein; or a polypeptide comprising an amino acid sequence having 90% or more (preferably 95% or more) identity to 25 the amino acid sequence may also be preferred.

[0032]

As used herein, a polypeptide "having substantially the same activity as RGMa protein" includes any polypeptide as long as the polypeptide has neurite

outgrowth inhibitory action.

[0033]

The amino acid substitution is preferably conservative substitution. As used herein, "conservative substitution" means replacing an amino acid residue with
 5 another chemically similar amino acid residue so as not to substantially alter the activity of the peptide. For example, substitution of one hydrophobic residue by another hydrophobic residue, substitution of one polar residue by another polar residue having the same electric charge, and the like are included. Examples of functionally similar amino acids with which such substitution is possible include, as
 10 nonpolar (hydrophobic) amino acids, alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine and methionine. Examples of polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, and cysteine. Examples of positively charged (basic) amino acids include arginine, histidine and lysine. Examples of negatively charged (acidic) amino acids include aspartic acid
 15 and glutamic acid.

[0034]

Binding of the RGMa binding protein of the present invention to RGMa means RGMa specific binding. More preferred is a RGMa-binding protein having a low dissociation constant (Kd) for human RGMa, for example, of 10^{-8} M or less,
 20 more preferably 10^{-9} M or less, still more preferably 10^{-10} M or less as the upper limit value, and for example without limitation, of 10^{-14} M or more, more preferably 10^{-13} or more as the lower limit value.

[0035]

The RGMa protein comprises an N-terminal domain and a C-terminal
 25 domain as a mature protein, but has neurite outgrowth inhibitory activity with the C-terminal domain alone. The RGMa-binding protein of the present invention preferably binds only to the C-terminal domain of RGMa to neutralize neurite outgrowth inhibitory activity. More preferred is a RGMa-binding protein having a

low dissociation constant (K_d) for the C-terminal domain of human RGMa, for example, of 10^{-8} M or less, more preferably 10^{-9} M or less, still more preferably 10^{-10} M or less as the upper limit value, and for example without limitation, of 10^{-14} M or more, more preferably 10^{-13} or more as the lower limit value.

5 [0036]

The RGMa-binding protein of the present invention does not inhibit binding between RGMa and neogenin. Here, the phrase "does not inhibit binding between RGMa and neogenin" means that, in the binding system of RGMa and neogenin shown in Examples described later, even when the concentration of RGMa-binding
10 protein is increased, the binding between RGMa and neogenin is not substantially decreased. For example, in the case where RGMa-binding protein is added to the binding system of RGMa and neogenin and its concentration is increased, if the concentration of the RGMa-binding protein showing IC_{50} is not less than 10 $\mu\text{g/mL}$, more preferably not less than 50 $\mu\text{g/mL}$, most preferably not less than 100 $\mu\text{g/mL}$, it
15 can be said that the RGMa-binding protein does not inhibit the binding between RGMa and neogenin.

[0037]

Neogenin used for the binding assay with RGMa is preferably neogenin of the same type as RGMa. In other words, it is preferred that mouse or human
20 neogenin is used for mouse or human RGMa, respectively. An example of human neogenin includes a protein having the amino acid sequence of SEQ ID NO: 10 in Sequence Listing. However, as long as it is capable of binding to RGMa, a protein having an amino acid sequence with 90% or more (preferably 95% or more) identity with SEQ ID NO: 10 in Sequence Listing may be preferred.

25 [0038]

The RGMa-binding protein of the present invention neutralizes the neurite outgrowth inhibiting activity of RGMa. The neurite outgrowth inhibitory activity can be evaluated by a neurite outgrowth assay shown in Examples described later.

Addition of RGMa inhibits neurite outgrowth, but addition of RGMa-binding protein prevents neurite outgrowth inhibition by RGMa. The RGMa-binding protein of the present invention can neutralize the neurite outgrowth inhibition by addition of RGMa by 50% or more, more preferably by 80% or more, and most preferably by 90% or more.

[0039]

Since amino acid sequences of RGMa proteins vary depending on the animal species, there are also differences in amino acid sequence between the human RGMa represented by SEQ ID NO: 1 in Sequence Listing, the mouse RGMa represented by SEQ ID NO: 2 in Sequence Listing, and the rat RGMa represented by SEQ ID NO: 3 in Sequence Listing. Since rodents such as mice and rats are generally used as experimental materials in pharmacological and safety tests of protein preparations such as antibody preparations, the RGMa-binding protein of the present invention preferably binds to mouse and/or rat RGMa, and more preferred are those having a low K_d for mouse and/or rat RGMa. RGMa-binding proteins whose K_d has the upper limit of, for example, 5×10^{-7} M or less, more preferably 10^{-8} M or less, still more preferably 10^{-9} M or less, and the lower limit value of, for example without limitation, 10^{-12} M or more, more preferably 10^{-11} or more are included.

[0040]

The RGMa binding protein of the present invention is preferably excellent in thermal stability. The thermal stability can be evaluated by a decrease in the binding with RGMa by heat treatment, and the RGMa binding protein of the present invention is preferably stable even by heat treatment at 60°C or higher, more preferably even by heat treatment at 65°C or higher, most preferably even by heat treatment at 70°C or higher.

[0041]

The binding site when the RGMa binding protein of the present invention

binds to RGMa is not particularly limited. For example, in human RGMa, binding to one or more of the following peptides is preferred: EEVVNAVEDWDSQG (SEQ ID NO: 26 in Sequence Listing) (amino acid numbers 298-311 of SEQ ID NO: 1 in Sequence Listing), NQQIDFQAFHTNAE (SEQ ID NO: 27 in Sequence Listing)
 5 (amino acid numbers 322-335 of SEQ ID NO: 1 in Sequence Listing), PTAPETFPYET (SEQ ID NO: 28 in Sequence Listing) (amino acid numbers 349-359 of SEQ ID NO: 1 in Sequence Listing), KLPVEDLYYQA (SEQ ID NO: 29 in Sequence Listing) (amino acid numbers 367-377 of SEQ ID NO: 1 in Sequence Listing). The RGMa binding protein of the present invention binds more preferably
 10 to SEQ ID NOS: 26 and 27 of the sequence listing, more preferably to SEQ ID NOS: 26 and 27 of the sequence listing and to SEQ ID NO: 28 or 29 of the sequence listing.

[0042]

Specific examples of RGMa-binding protein include anti-RGMa antibody,
 15 RGMa-binding scaffold protein, and fusion proteins thereof.

[0043]

Anti-RGMa Antibody

The anti-RGMa antibody of the present invention includes polyclonal or monoclonal antibodies obtained by using the RGMa protein or a partial fragment
 20 thereof (for example, a fragment containing one or more of SEQ ID NOS: 26 to 29 in the above sequence listing) as an antigen and immunizing mammals such as mice with the antigens; chimeric antibodies and humanized antibodies produced using gene recombination technology; human antibodies produced using, for example, human antibody-producing transgenic animals; and the like. When the antibody of
 25 the present invention is administered as a pharmaceutical to humans, a humanized antibody or a human antibody is preferable from the viewpoint of side effects.

[0044]

Antigens may be directly used for immunization or may be used as a

complex with a carrier protein. For preparing a complex of an antigen and a carrier protein, condensing agents such as glutaraldehyde, carbodiimide and maleimide active ester can be used. Examples of the carrier protein include bovine serum albumin, thyroglobulin, hemocyanin, and KLH.

5 [0045]

Examples of mammals to be immunized include mice, rats, hamsters, guinea pigs, rabbits, cats, dogs, pigs, goats, horses and cattle, and inoculation methods include subcutaneous, intramuscular or intraperitoneal administration. Upon administration, antigens may be administered in admixture with complete Freund's adjuvant or incomplete Freund's adjuvant, and administration is usually carried out
10 once every 2 to 5 weeks. Antibody-producing cells obtained from the spleen or lymph nodes of the immunized animals are fused with myeloma cells and isolated as hybridomas. As the myeloma cells, those derived from a mammal such as mouse, rat, or human are used.

15 [0046]

Polyclonal Antibody

Polyclonal antibodies can be obtained by existing common production methods. That is, polyclonal antibodies can be obtained from serum obtained from animals subjected to immunization, for example, by immunizing a mammal as
20 described above with an antigen as described above together with Freund's adjuvant as necessary.

[0047]

Monoclonal Antibody

Specifically, monoclonal antibodies can be obtained as follows. That is, an
25 antigen as described above is used as an immunogen, and the immunogen is injected or transplanted one or several times in combination with Freund's adjuvant, if necessary, to a mammal as described above subcutaneously, intramuscularly, intravenously, into a footpad or intraperitoneally for immunization. Generally,

immunization is performed 1 to 4 times every 1 to 14 days from the initial immunization, and antibody-producing cells are obtained from the mammal immunized from about 1 to 5 days after the final immunization.

[0048]

- 5 Monoclonal antibodies can be obtained using methods well known to those skilled in the art (for example, "Current Protocols in Molecular Biology" (John Wiley & Sons (1987)), Antibodies: A Laboratory Manual, Ed. Harlow and David Lane, Cold Spring Harbor Laboratory (1988))).

[0049]

- 10 Preparation of "hybridomas" secreting monoclonal antibodies can be carried out according to the method of Köhler and Milstein et al. (Nature, 256, 495, 1975) and methods similar thereto. That is, Hybridomas are prepared by fusing an antibody-producing cell contained in a spleen or the like obtained from an immunized mammal with a myeloma cell having no autoantibody producing ability
- 15 derived from a mammal, preferably mouse, rat or human.

[0050]

- Examples of myeloma cells which can be used for cell fusion include mouse-derived myeloma P3/X63-Ag8.653 (653), P3/NSI/1-Ag4-1 (NS-1), P3/X63-Ag8.U1 (P3U1), SP2/0-Ag14 (Sp2/O, Sp2), PAI, F0 and BW5147, rat-derived
- 20 myeloma 210RCY3-Ag.2.3., and human-derived myeloma U-266AR1, GM1500-6TG-A1-2, UC729-6, CEM-AGR, D1R11 and CEM-T15.

[0051]

- Examples of fusion accelerators include polyethylene glycol and the like. In general, antibody-producing cells and myeloma cells at a number ratio of usually
- 25 about 1: 1 to 10: 1 are allowed to react, using polyethylene glycol (average molecular weight: 1000 to 4000) at a concentration of about 20 to 50%, at a temperature of 20 to 40°C, preferably 30 to 37°C for about 1 to 10 minutes, whereby cell fusion can be carried out.

[0052]

Screening of hybridoma clones producing monoclonal antibodies can be carried out by culturing the hybridomas, for example, in microtiter plates and measuring the reactivity of the culture supernatants in the wells to the immunogen by immunochemical methods such as ELISA.

[0053]

In the screening of the antibody-producing hybridomas, in addition to the binding assay with RGMa protein, whether the antibody does not inhibit the binding between RGMa protein and neogenin and whether the antibody neutralizes the function of RGMa protein (neurite outgrowth inhibitory activity) are also evaluated. These screening methods allow selection of the anti-RGMa antibody of the present invention.

[0054]

Clones can be further obtained from the wells containing hybridomas producing the desired antibodies by cloning using limiting dilution. Selection and breeding of hybridomas are usually carried out in an animal cell culture medium containing 10 to 20% fetal bovine serum supplemented with HAT (hypoxanthine, aminopterin and thymidine).

[0055]

Monoclonal antibodies from hybridomas can be produced by culturing the hybridomas in vitro or growing them in vivo, for example, in ascitic fluid of mammals such as mice and rats and isolating monoclonal antibodies from the resulting culture supernatant or the ascitic fluid of the mammal.

[0056]

When cultured in vitro, hybridomas are grown, maintained, and stored in accordance with various conditions such as the characteristics of and the culture method for the cells species to be cultured, and a nutrient medium suitable for producing monoclonal antibodies in the culture supernatant can be used.

[0057]

Examples of basic media include a low-calcium medium such as Ham's F12 medium, MCDB 153 medium or low-calcium MEM medium and a high-calcium medium such as MCDB 104 medium, MEM medium, D-MEM medium, RPMI 1640 medium, ASF 104 medium or RD medium. The basic media can contain, for example, serum, hormones, cytokines and/or various inorganic or organic substances according to the purpose.

[0058]

Monoclonal antibodies can be isolated and purified by, for example, subjecting the above-mentioned culture supernatant or ascitic fluid to saturated ammonium sulfate, euglobulin precipitation method, caproic acid method, caprylic acid method, ion exchange chromatography (such as DEAE or DE52) or affinity column chromatography such as anti-immunoglobulin column or protein A column chromatography. Specifically, purification of the monoclonal antibody can be carried out by any methods known as immunoglobulin purification method, and can be easily achieved by means such as ammonium sulfate fractionation, PEG fractionation, ethanol fractionation, and affinity chromatography utilizing an anion exchanger and further using RGMA proteins.

[0059]

Monoclonal antibodies can also be obtained by a phage display method. In the phage display method, phages selected from an optional phage antibody library are screened using the desired immunogen and phages having desired binding capacity to the immunogen are selected. Next, the antibody-corresponding sequence contained in the phage is isolated or sequenced and an expression vector comprising a nucleic acid molecule encoding an antibody or an antigen binding domain is constructed based on the isolated sequence or the determined sequence information. Finally, monoclonal antibodies can be produced by culturing cell lines transfected with such expression vectors. A human antibody library can be used as a phage

antibody library to generate human antibodies having desired binding properties.

[0060]

As a scaffold protein, for example, a Kunitz domain of human serine protease inhibitor and an extracellular domain of human fibronectin are utilized, and
 5 the sequence of a target binding site on the scaffold can be modified to generate a scaffold protein which binds to RGMa (Clifford Mintz et.al BioProcess International, 2013, Vol.11(2), pp40-48).

[0061]

Fusion proteins include RGMa-binding proteins bound chemically or
 10 genetically to function molecules other than the RGMa-binding protein of the present application such as nonpeptidic polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, growth factors (e.g., TGF- β , NGF, neurotrophin), albumin, enzymes, and other antibodies.

[0062]

15 When PEG is bound as a functional molecule, PEG can be used having a molecular weight of, without limitation, 2,000 to 100,000 Da, more preferably 10,000 to 50,000 Da, which may be linear or branched. By using, for example, an NHS active group, PEG can be bound, for example, to N-terminal amino groups of amino acids of the RGMa-binding protein.

20 [0063]

In the case of using a radioactive substance as a functional molecule, for example, ^{131}I , ^{125}I , ^{90}Y , ^{64}Cu , ^{99}Tc , ^{77}Lu or ^{211}At is used. Radioactive substances can be directly bound to the RGMa-binding protein by, for example, chloramine-T method.

25 [0064]

When using a toxin as a functional molecule, for example, bacterial toxins (e.g., diphtheria toxin), phytotoxins (e.g., ricin), small toxins (e.g., geldanamycin), maytansinoids and calicheamicin are used.

[0065]

When using a low molecular weight compound as a functional molecule, for example, daunomycin, doxorubicin, methotrexate, mitomycin, neocarzinostatin, vindesine and fluorescent dyes such as FITC are used.

5 [0066]

When using an enzyme as a functional molecule, for example, luciferase (e.g., firefly luciferase and bacterial luciferase; US Pat. No. 4,737,456), malate dehydrogenase, urease, peroxidase (e.g., horseradish peroxidase (HRPO)), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidase (e.g.,
 10 glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase), heterocyclic oxidase (e.g., uricase and xanthine oxidase), lactoperoxidase, and microperoxidase are used.

[0067]

Examples of linkers used for chemically bonding a toxin, a low molecular
 15 weight compound or an enzyme include divalent radicals (e.g., alkylene, arylene, heteroarylene), a repeating unit of a linker or alkoxy represented by $-(CR_2)_nO(CR_2)_n-$ (wherein R is an optional substituent, and n is a positive integer) (e.g., polyethyleneoxy, PEG and polymethyleneoxy) and alkylamino (e.g., polyethyleneamino, JeffamineTM) and a diacid ester and amide (e.g., succinate,
 20 succinamide, diglycolate, malonate, and caproamide). Chemical modification methods for binding functional molecules have already been established in this field (D.J.King., Applications and Engineering of Monoclonal antibodies., 1998, T.J. International Ltd, Monoclonal Antibody-Based Therapy of Cancer., 1998, Marcel Dekker Inc; Chari et al., Cancer Res., 1992 Vol 152:127; Liu et al., Proc Natl Acad
 25 Sci USA., 1996 Vol 93:8681).

[0068]

A preferred embodiment of the RGMa-binding protein of the present invention is a chimeric antibody. As the "chimeric antibody", a chimeric antibody in

which the variable region is a variable region derived from an immunoglobulin of a non-human animal (such as mouse, rat, hamster or chicken) and the constant region is a constant region of human immunoglobulin is exemplified. A chimeric antibody can be prepared, for example, by immunizing a mouse with an antigen, cutting out a
5 variable region that binds to the antigen from the gene encoding the mouse monoclonal antibody, and combining the variable region with a constant region of an antibody derived from human bone marrow. The constant region derived from human immunoglobulin has a unique amino acid sequence depending on the isotype such as IgG (IgG1, IgG2, IgG3 and IgG4), IgM, IgA (IgA1 and IgA2), IgD and IgE,
10 but the constant region of the recombinant chimeric antibody according to the present invention may be a constant region of human immunoglobulin belonging to any isotype. The constant region is preferably a constant region of human IgG. An expression vector can be prepared using the gene of the chimeric antibody thus prepared. Host cells are transformed with the expression vector to obtain chimeric
15 antibody-producing transformant cells, and then the transformed cells are cultured to obtain the desired chimeric antibody from the culture supernatant.

[0069]

Another preferred embodiment of the RGMa-binding protein of the present invention is a humanized antibody. The "humanized antibody" in the present
20 invention is an antibody obtained by grafting only the DNA sequence of the antigen binding site (CDR; complementarity determining region) of a nonhuman animal antibody such as mouse to a human antibody gene (CDR grafting). Humanized antibodies can be prepared by referring to the methods described in, for example, Japanese Translated PCT Patent Application Laid-open No. Hei 4-506458 and
25 Japanese Patent No. 2912618. Specifically, a humanized antibody is contemplated characterized in that part or all of the CDRs are CDRs derived from monoclonal antibodies of non-human mammals (such as mouse, rat and hamster), that the framework regions of the variable region are framework regions of variable regions

derived from human immunoglobulin, and that the constant regions are constant regions derived from human immunoglobulin.

[0070]

The humanized antibody of the present invention can be produced, for
5 example, as follows, but it goes without saying that the production method is not limited thereto.

[0071]

For example, a recombinant humanized antibody derived from a mouse
monoclonal antibody can be produced by genetic engineering with reference to
10 Japanese Translated PCT Patent Application Laid-open Nos. Hei 4-506458 and Sho 62-296890. That is, DNA coding for mouse heavy chain CDR portion and DNA coding for mouse light chain CDR portion are isolated from hybridomas producing a mouse monoclonal antibody, and a human heavy chain gene coding for the whole region other than CDR of human heavy chain and a human light chain gene coding
15 for the whole region other than CDR of human light chain are isolated from a human immunoglobulin gene.

[0072]

The human heavy chain gene to which the isolated DNA coding for mouse heavy chain CDR portion is grafted is introduced into an appropriate expression
20 vector so that expression thereof is possible. Similarly, the human light chain gene to which the DNA coding for mouse light chain CDR portion is grafted is introduced into another appropriate expression vector so that expression thereof is possible. Alternatively, human heavy and light chain genes to which mouse CDR is grafted may be introduced into the same expression vector so that expression thereof is
25 possible. Host cells are transformed with the expression vector thus prepared to obtain humanized antibody-producing transformant cells, and then the transformed cells are cultured to obtain the desired humanized antibody from the culture supernatant.

[0073]

Another preferred embodiment of the RGMa-binding protein of the present invention is a human antibody. A human antibody refers to an antibody in which all regions including heavy chain variable regions and heavy chain constant regions and
 5 light chain variable regions and light chain constant regions constituting the immunoglobulin are derived from genes encoding human immunoglobulin. Human antibodies can be prepared by introducing human antibody genes into mice. Human antibodies can be produced in the same manner as the above-mentioned method for preparing polyclonal antibodies or monoclonal antibodies, specifically, for example,
 10 by immunizing a transgenic animal prepared by integrating at least human immunoglobulin genes into a gene locus of a mammal other than a human such as a mouse.

[0074]

For example, transgenic mice that produce human antibodies can be
 15 prepared according to the methods described, for example, in Nature Genetics, Vol.7, p.13-21, 1994; Nature Genetics, Vol.15, p.146-156, 1997; Japanese Translated PCT Patent Application Laid-open Nos. Hei 4-504365 and Hei 7-509137; WO 94/25585; Nature, Vol.368, p.856-859, 1994; and Japanese Translated PCT Patent Application Laid-open No. Hei 6-500233. Specific examples of the transgenic mice include
 20 HuMabTM mouse (Medarex, Princeton NJ), KMTM mouse (Kirin Pharma Company, Japan), and KM (FC γ RIIb-KO) mouse.

[0075]

Specific examples of the monoclonal antibody of the present invention include those in which CDRs in the heavy chain variable region comprise the amino
 25 acid sequences of SEQ ID NOS: 33 (HCDR 1), 34 (HCDR 2) and 35 (HCDR 3) in Sequence Listing and in which CDRs in the light chain variable region comprise the amino acid sequences of SEQ ID NOS: 30 (LCDR 1), 31 (LCDR 2) and 32 (LCDR 3) in Sequence Listing. One to several amino acids in one or more of the CDRs may

be substituted as long as the properties of the antibody of the present invention of having the ability to bind to RGMa, not inhibiting the binding between RGMa and neogenin, and neutralizing the neurite outgrowth inhibitory activity of RGMa are maintained. One to several means, for example, one or two. The amino acid
5 substitution is preferably conservative substitution in order to maintain the properties of the present invention. Maintaining the properties of the antibody means that these properties are maintained to the same degree, for example, 80% or more, preferably 90% or more, more preferably 95% or more as compared with the properties before the CDR amino acid sequence modifications. Maintenance also includes
10 improvement.

[0076]

The region other than CDRs is not particularly limited as long as it is a sequence that can maintain the structure as an antibody and exert its function, and may be any of the sequences derived from mouse, human, and other mammals,
15 chimeric sequences thereof, and artificial sequences. In the case of comprising a constant region, the amino acid sequences of the constant regions in heavy chain and light chain are exemplified by those described in Nucleic Acids Research vol.14, p1779, 1986, The Journal of Biological Chemistry vol.257, p1516, 1982 and Cell vol.22, p197, 1980.

20 [0077]

Examples of mouse antibodies having these CDRs include antibodies in which the light chain has the amino acid sequence of SEQ ID NO: 4 in Sequence Listing and in which the heavy chain has the amino acid sequence of SEQ ID NO: 5 in Sequence Listing. In these amino acid sequences, there may be substitution,
25 deletion, addition or insertion of one or several (1 to 20, 1 to 10 or 1 to 5) amino acids as long as the properties of the antibody of having the ability to bind to RGMa, not inhibiting the binding between RGMa and neogenin, and neutralizing the neurite outgrowth inhibitory activity of RGMa are maintained. Such substitution, deletion or

addition may be introduced into CDRs, but it is preferably introduced into a region other than the CDRs. The amino acid substitution is preferably conservative substitution in order to maintain the properties of the present invention.

[0078]

5 Mouse/human chimeric antibodies in which constant regions in the above-mentioned mouse antibody are derived from human are also included. An example of such mouse/human chimeric antibodies is an antibody in which the light chain has the amino acid sequence of SEQ ID NO: 8 in Sequence Listing (the variable region extends from 1 to 107) and in which the heavy chain has the amino acid sequence of
10 SEQ ID NO: 9 in Sequence Listing (the variable region extends from 1 to 116). In these amino acid sequences, there may be substitution, deletion, addition or insertion of one or several (1 to 20, 1 to 10 or 1 to 5) amino acids as long as the properties of the antibody of having the ability to bind to RGMa, not inhibiting the binding between RGMa and neogenin, and neutralizing the neurite outgrowth inhibitory
15 activity of RGMa are maintained. Such substitution, deletion or addition may be introduced into CDRs, but it is preferably introduced into a region other than the CDRs. The amino acid substitution is preferably conservative substitution in order to maintain the properties of the present invention.

[0079]

20 Further, humanized antibodies in which the region other than CDRs is derived from human are exemplified. An example of such humanize antibodies is an antibody in which the heavy chain has an amino acid sequence of any one of SEQ ID NOS: 11 to 18 (the variable region is up to the 116th residue on the N terminal side) and in which the light chain has an amino acid sequence of any one of SEQ ID NOS:
25 19-25 in Sequence Listing (the variable region extends from the 1st to 107th residues on the N-terminal side).

In the amino acid sequences of the humanized antibody (heavy chain: SEQ ID NOS: 11-18 in Sequence Listing, light chain: SEQ ID NOS: 19 to 25 in Sequence

Listing), there may be substitution, deletion, addition or insertion of one or several (1 to 20, 1 to 10 or 1 to 5) amino acids as long as the properties of the antibody of having the ability to bind to RGMa, not inhibiting the binding between RGMa and neogenin, and neutralizing the neurite outgrowth inhibitory activity of RGMa are maintained. Such substitution, deletion or addition may be introduced into CDRs, but it is preferably introduced into a region other than the CDRs. The amino acid substitution is preferably conservative substitution in order to maintain the properties of the present invention.

[0080]

10 The heavy chain amino acid sequence and the light chain amino acid sequence may be any combination thereof, but particularly preferred is an antibody having heavy chains comprising the amino acid sequence of SEQ ID NO: 15 in Sequence Listing and light chains comprising the amino acid sequence of SEQ ID NO: 19 in Sequence Listing. In the amino acid sequence of SEQ ID NO: 15 in
15 Sequence Listing, the amino acid sequence corresponding to the heavy chain variable region is shown in SEQ ID NO: 41 in Sequence Listing and the amino acid sequence corresponding to the light chain variable region is shown in SEQ ID NO: 42 in Sequence Listing. Thus, the particularly preferred antibody of the present invention is an antibody in which the heavy chain variable region has the amino acid sequence
20 of SEQ ID NO: 41 in Sequence Listing and in which the light chain variable region has the amino acid sequence of SEQ ID NO: 42 in Sequence Listing.

 In these amino acid sequences, there may be substitution, deletion, addition or insertion of one or several (1 to 20, 1 to 10 or 1 to 5) amino acids as long as the properties of the antibody of having the ability to bind to RGMa, not inhibiting the
25 binding between RGMa and neogenin, and neutralizing the neurite outgrowth inhibitory activity of RGMa are maintained. Such substitution, deletion or addition may be introduced into CDRs, but it is preferably introduced into a region other than the CDRs. The amino acid substitution is preferably conservative substitution in

order to maintain the properties of the present invention.

In the amino acid sequence of the antibody of the present invention comprising substitution, deletion or the like in the amino acid sequence of SEQ ID NO: 41 and/or 42 in Sequence Listing as described above, the heavy chain variable
5 region is an amino acid sequence having 90% or more (more preferably 95%, 96%, 97%, 98%, 99% or more) identity with SEQ ID NO: 41 of the sequence listing, and the light chain variable region is an amino acid sequence having 90% or more (more preferably 95%, 96%, 97%, 98%, 99% or more) identity with SEQ ID NO: 42 of the sequence listing.

10 [0081]

Other specific examples of the monoclonal antibody of the present invention include those in which CDRs in the heavy chain variable region comprise the amino acid sequences of SEQ ID NOS: 39 (HCDR 1), 40 (HCDR 2) and SFG (HCDR 3) in Sequence Listing and in which CDRs in the light chain variable region comprise the
15 amino acid sequences of SEQ ID NOS: 36 (LCDR 1), 37 (LCDR 2) and 38 (LCDR 3) in Sequence Listing. One to several amino acids in one or more of the CDRs may be substituted as long as the properties of the antibody of the present invention of having the ability to bind to RGMa, not inhibiting the binding between RGMa and neogenin, and neutralizing the neurite outgrowth inhibitory activity of RGMa are
20 maintained.

One to several means, for example, one or two. The amino acid substitution is preferably conservative substitution in order to maintain the properties of the present invention.

The region other than CDRs is not particularly limited as long as it is a
25 sequence that can maintain the structure as an antibody and exert its function, and may be any of the sequences derived from mouse, human, and other mammals, chimeric sequences thereof, and artificial sequences. In the case of comprising a constant region, the amino acid sequences of the constant regions in heavy chain and

light chain are exemplified by those described in Nucleic Acids Research vol.14, p1779, 1986, The Journal of Biological Chemistry vol.257, p1516, 1982 and Cell vol.22, p197, 1980.

[0082]

5 Examples of mouse antibodies having these CDRs include antibodies in which the light chain has the amino acid sequence of SEQ ID NO: 6 in Sequence Listing and in which the heavy chain has the amino acid sequence of SEQ ID NO: 7 in Sequence Listing. In these amino acid sequences, there may be substitution, deletion, addition or insertion of one or several (1 to 20, 1 to 10 or 1 to 5) amino
10 acids as long as the properties of the antibody of having the ability to bind to RGMa, not inhibiting the binding between RGMa and neogenin, and neutralizing the neurite outgrowth inhibitory activity of RGMa are maintained. Such substitution, deletion or addition may be introduced into CDRs, but it is preferably introduced into a region other than the CDRs. The amino acid substitution is preferably conservative
15 substitution in order to maintain the properties of the present invention.

[0083]

As the above-mentioned mouse antibody, chimeric antibodies whose constant regions are derived from human are also included. Humanized antibodies in which the region other than CDRs is derived from human are further included.

20 [0084]

The anti-RGMa antibody of the present invention includes multispecific antibodies, functionally modified antibodies, and conjugated antibodies having CDRs comprising specific amino acid sequences (for example, amino acid sequences of SEQ ID NO: 30 in Sequence Listing for LCDR1, SEQ ID NO: 31 in Sequence
25 Listing for LCDR2, SEQ ID NO: 32 in Sequence Listing for LCDR3, SEQ ID NO: 33 in Sequence Listing for HCDR1, SEQ ID NO: 34 in Sequence Listing for HCDR2, and SEQ ID NO: 35 in Sequence Listing for HCDR3), or having variable regions comprising specific amino acid sequences (for example, amino acid

sequences of SEQ ID NO: 41 in Sequence Listing for heavy chain variable region, and SEQ ID NO: 42 for light chain variable region).

[0085]

The anti-RGMA antibody of the present invention itself can be bound to an
 5 antibody having another antigen binding specificity other than anti-RGMA specificity by genetic engineering techniques to prepare multispecific antibodies such as bispecific antibodies. The genetic engineering techniques have already been established in this field. For example, by using a technique for DVD-Ig in which variable regions are connected in series (Wu et al., Nature Biotechnology 25(11),
 10 1290 (2007)) or a technique for ART-Ig in which heavy chains of two types of antibodies binding to different antigens are combined by modifying the Fc region of an antibody (Kitazawa et al., Nature Medicine 18(10), 1570(2012), desired bispecific antibodies can be obtained. Other antigens than RGMA include, but not limited to, factors inhibiting neurite outgrowth such as Nogo, MAG, Omgp, CSPG, Sema 3A
 15 and Lingo-1, and immune-related molecules such as TNF- α , IL-6 receptor, CD3, CD20, α 4 integrin, BLys, Thymic Stromal Lymphopoietin, IgE, IL-1, IL-2, IL-4, IL-5, IL-6, IL-13, IL-17, IL-23 and IL-25.

[0086]

Functionally modified antibodies are exemplified as modified molecules of
 20 the anti-RGMA antibody of the present invention. Functionally modified antibody means an antibody in which functions such as cell killing function, complement activating function and function to extend blood half-life are modified mainly by modifying the Fc region or the like (Shitara, Journal of the Pharmaceutical Society of Japan, 2009, Vol. 129(1), p3; Ishii et al., Nippon Yakubutsugaku Zasshi (Folia
 25 Pharmacologica Japonica), 2010, Vol.136(5), p280; Hashiguchi et al., The Journal of Japanese Biochemical Society, 2010, Vol.82(8),p710).

[0087]

Functionally modified antibodies of the anti-RGMA antibody are prepared

by the following method. For example, when the anti-RGMa antibody of the present application is produced using, as host cells, CHO cells whose α 1,6-fucosyltransferase (FUT 8) gene has been disrupted, antibodies with reduced content of sugar chain fucose and increased cell killing function are obtained, and when the anti-RGMa antibody of the present application is produced using, as a host cell, CHO cells into which FUT8 gene has been introduced, antibodies with low cell killing function are obtained (WO 2005/035586, WO 2002/31140 and WO 00/61739). The complement activation function can be regulated by modifying amino acid residues in the Fc region (U.S. Patent Nos: 6737056, 7297775 and 7317091). The blood half-life extension can be achieved by using Fc region variants with increased binding to FcRn which is one of Fc receptors (Hashiguchi et al., The Journal of Japanese Biochemical Society, 2010, Vol.82 (8), p710). These functionally modified antibodies can be produced by genetic engineering techniques.

[0088]

Conjugated antibodies are exemplified as modified molecules of the anti-RGMa antibody of the present invention. Examples of the conjugated antibody include conjugated antibodies in which anti-RGMa antibodies are bound chemically or genetically to function molecules other than the anti-RGMa antibody in the present application such as nonpeptidic polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, growth factors (e.g., TGF- β , NGF, neurotrophin), albumin, enzymes, and other antibodies.

[0089]

When PEG is bound as a functional molecule, PEG can be used having a molecular weight of, without limitation, 2,000 to 100,000 Da, more preferably 10,000 to 50,000 Da, which may be linear or branched. By using, for example, an NHS active group, PEG can be bound, for example, to N-terminal amino groups of amino acids of antibodies.

[0090]

In the case of using a radioactive substance as a functional molecule, for example, ^{131}I , ^{125}I , ^{90}Y , ^{64}Cu , ^{99}Tc , ^{77}Lu or ^{211}At is used. Radioactive substances can be directly bound to antibodies by, for example, chloramine-T method.

[0091]

- 5 When using a toxin as a functional molecule, for example, bacterial toxins (e.g., diphtheria toxin), phytotoxins (e.g., ricin), small toxins (e.g., geldanamycin), maytansinoids and calicheamicin are used.

[0092]

- 10 When using a low molecular weight compound as a functional molecule, for example, daunomycin, doxorubicin, methotrexate, mitomycin, neocarzinostatin, vindesine and fluorescent dyes such as FITC are used.

[0093]

- 15 When using an enzyme as a functional molecule, for example, luciferase (e.g., firefly luciferase and bacterial luciferase; US Pat. No. 4,737,456), malate dehydrogenase, urease, peroxidase (e.g., horseradish peroxidase (HRPO)), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidase (e.g., glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase), heterocyclic oxidase (e.g., uricase and xanthine oxidase), lactoperoxidase, and microperoxidase are used.

- 20 [0094]

- 25 Examples of linkers used for chemically bonding a toxin, a low molecular weight compound or an enzyme include divalent radicals (e.g., alkylene, arylene, heteroarylene), a repeating unit of a linker or alkoxy represented by $-(\text{CR}_2)_n\text{O}(\text{CR}_2)_n-$ (wherein R is an optional substituent, and n is a positive integer) (e.g., polyethyleneoxy, PEG and polymethyleneoxy) and alkylamino (e.g., polyethyleneamino, JeffamineTM) and a diacid ester and amide (e.g., succinate, succinamide, diglycolate, malonate, and caproamide). Chemical modification methods for binding functional molecules have already been established in this field

(D.J.King., Applications and Engineering of Monoclonal antibodies., 1998 T.J. International Ltd, Monoclonal Antibody-Based Therapy of Cancer., 1998 Marcel Dekker Inc; Chari et al., Cancer Res., 1992 Vol152:127; Liu et al., Proc Natl Acad Sci USA., 1996 Vol 93:8681).

5 [0095]

"Antigen binding fragments" of antibodies in the present invention means a partial region having antigen binding property, of the above-described antibodies, including, in particular, $F(ab')_2$, Fab', Fab, Fv (variable fragment of antibody), disulfide-linked Fv, single-chain antibody (scFv), and polymers thereof. Antigen-
10 binding fragments further include conjugated antigen-binding fragments bound chemically or genetically to function molecules other than the anti-RGMa antibody in the present application such as nonpeptidic polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, growth factors (e.g., TGF- β , NGF, neurotrophin), albumin, enzymes, and other
15 antibodies.

[0096]

As used herein, " $F(ab')_2$ " and "Fab" means antibody fragments which are produced by treating immunoglobulins with a protease pepsin or papain and are generated by digestion upstream and downstream of the disulfide bond existing
20 between two heavy chains in the hinge region. For example, papain treatment of IgG can cause cleavage upstream of the disulfide bond existing between two heavy chains in the hinge region to produce of two homologous antibody fragments each comprising a light chain comprising a VL (light chain variable region) and a CL (light chain constant region) and a heavy chain fragment comprising a VH (heavy
25 chain variable region) and a CH γ 1 (γ 1 region within heavy chain constant region) in which the light chain and the heavy chain fragment are linked to each other via a disulfide bond at C-terminal domain. Each of the two homologous antibody fragments is referred to as Fab. Pepsin treatment of IgG can cause cleavage

downstream of the disulfide bond existing between two heavy chains in the hinge region to produce an antibody fragment slightly larger than one in which the two Fabs are linked to each other at the hinge region. This antibody fragment is referred to as F(ab')₂.

5 [0097]

Conjugated antigen-binding fragments are exemplified as modified molecules of the antigen-binding fragment of the anti-RGMa antibody of the present invention. Examples of the conjugated antigen-binding fragment include those in which a partial region having the antigen-binding property of the anti-RGMa
10 antibody is bound chemically or genetically to a function molecule other than the anti-RGMa antibody in the present application such as nonpeptidic polymers such as polyethylene glycol (PEG), radioactive substances, toxins, low molecular weight compounds, cytokines, growth factors (e.g., TGF- β , NGF, neurotrophin), albumin, enzymes, and other antibodies.

15 [0098]

When PEG is bound as a functional molecule, PEG can be used having a molecular weight of, without limitation 2,000 to 100,000 Da, more preferably 10,000 to 50,000 Da, which may be linear or branched. PEG can be bound, for example, to the N-terminal amino group of a partial region having the antigen-binding property
20 of the anti-RGMa antibody by using, for example, an NHS active group.

[0099]

In the case of using a radioactive substance as a functional molecule, for example, ¹³¹I, ¹²⁵I, ⁹⁰Y, ⁶⁴Cu, ⁹⁹Tc, ⁷⁷Lu or ²¹¹At is used. Radioactive substances can be directly bound to a partial region having the antigen-binding property of the anti-
25 RGMa antibody by, for example, chloramine-T method.

[0100]

When using a toxin as a functional molecule, for example, bacterial toxins (e.g., diphtheria toxin), phytotoxins (e.g., ricin), small toxins (e.g., geldanamycin),

maytansinoids and calicheamicin are used.

[0101]

When using a low molecular weight compound as a functional molecule, for example, daunomycin, doxorubicin, methotrexate, mitomycin, neocarzinostatin,
 5 videsine and fluorescent dyes such as FITC are used.

[0102]

When using an enzyme as a functional molecule, for example, luciferase (e.g., firefly luciferase and bacterial luciferase; US Pat. No. 4,737,456), malate dehydrogenase, urease, peroxidase (e.g., horseradish peroxidase (HRPO)), alkaline
 10 phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidase (e.g., glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase), heterocyclic oxidase (e.g., uricase and xanthine oxidase), lactoperoxidase, and microperoxidase are used.

[0103]

15 Examples of linkers used for chemically bonding a toxin, a low molecular weight compound or an enzyme include divalent radicals (e.g., alkylene, arylene, heteroarylene), a repeating unit of a linker or alkoxy represented by $-(CR_2)_nO(CR_2)_n-$ (wherein R is an optional substituent, and n is a positive integer) (e.g., polyethyleneoxy, PEG and polymethyleneoxy) and alkylamino (e.g.,
 20 polyethyleneamino, JeffamineTM) and a diacid ester and amide (e.g., succinate, succinamide, diglycolate, malonate, and caproamide). Chemical modification methods for binding functional molecules have already been established in this field (D.J.King., Applications and Engineering of Monoclonal antibodies., 1998 T.J. International Ltd, Monoclonal Antibody-Based Therapy of Cancer., 1998 Marcel
 25 Dekker Inc; Chari et al., Cancer Res., 1992 Vol152:127; Liu et al., Proc Natl Acad Sci USA., 1996 Vol 93:8681).

[0104]

In the anti-RGMA antibody comprising CDRs or variable regions having the

specific amino acid sequences of the present invention, the constant region preferably is a constant region of human IgG (IgG1, IgG2, IgG3 or IgG4) for maintenance with a long half-life in blood.

[0105]

5 The present invention also includes an anti-RGMa antibody which competes with the antibody having the amino acid sequences of the specific CDRs as described above for binding to RGMa proteins, and antigen binding fragments thereof. The antibody which competes with the antibody having the amino acid sequences of the specific CDRs as described above for binding to RGMa proteins include epitopes in
10 the regions selected from Glu 298 to Gly 311, Asn 322 to Glu 335, Lys 367 to Ala 377, and Pro 349 to Thr 359.

 The antibody can be obtained (screened) or evaluated by allowing the antibody to coexist in the binding system of the antibody having the CDR sequences as described above and RGMa proteins. For example, the antibody can be obtained
15 by screening using the following surface plasmon resonance (SPR) method.

[0106]

 Biotinylated human RGMa protein (4 $\mu\text{g/mL}$) as a ligand is loaded on an avidin-immobilized sensor chip to immobilize human RGMa proteins equivalent to 1300 to 1600 RU. Next, an optional anti-RGMa antibody (15 $\mu\text{g/mL}$) is loaded as an
20 analyte and bound to the human RGMa protein immobilized on the sensor chip. By repeating this a plurality of times, a state in which the optional anti-RGMa antibody is bound to all of the human RGMa protein molecules on the sensor chip is created (saturated state) and the amount of binding in the saturated state (saturated binding amount 1) is determined.

25 A similar experiment is carried out with the anti-RGMa antibody comprising the amino acid sequences of the specific CDRs of the present invention to determine the amount of binding in the saturated state (saturated binding amount 2).

Next, the human RGMa proteins on the sensor chip are saturated with the anti-RGMa antibody comprising the amino acid sequences of the specific CDRs of the present invention, and then an optional anti-RGMa antibody (15 µg/mL) is loaded as an analyte to investigate whether the optional anti-RGMa antibody binds
5 additionally to the human RGMa protein saturated with the anti-RGMa antibody comprising the amino acid sequences of the specific CDRs of the invention.

If the optional anti-RGMa antibody can bind additionally to the human RGMa protein saturated with the anti-RGMa antibody comprising the amino acid sequences of the specific CDRs of the invention while showing the saturated binding
10 amount 1 of an optional anti-RGMa antibody calculated above, then the antibody is judged as "not competing". On the other hand, if the optional anti-RGMa antibody can not bind additionally to the human RGMa protein saturated with the anti-RGMa antibody comprising the amino acid sequences of the specific CDRs of the invention, then the antibody is judged as "competing". Even if the optional anti-RGMa
15 antibody can bind additionally to the human RGMa protein saturated with the anti-RGMa antibody comprising the amino acid sequences of the specific CDRs of the invention, when the added binding amount does not reach the saturated binding amount 1 with a significant difference, then the antibody is judged as "competing". Significant differences are examined by general statistical methods (for example,
20 Student's t-test), and the significance level is set to 5% or less.

[0107]

The anti-RGMa antibody which competes with an anti-RGMa antibody comprising the specific CDR amino acid sequence as described above for binding with RGMa may be an antibody derived from any animal such as mouse, human, rat,
25 rabbit, goat, or camel antibody, or may be a chimeric or humanized antibody which is a combination of these antibodies, but preferably is a chimeric, humanized, or human antibody.

[0108]

Nucleic Acid Molecules of the Present Invention

Examples of the nucleic acid molecules of the present invention include polynucleotides in which the region encoding a heavy chain variable region comprises a base sequence encoding the amino acid sequence of SEQ ID NOS: 33, 34, and 35 in Sequence Listing, respectively (in which one or several amino acids may be substituted, deleted, inserted or added) and the region encoding a light chain variable region comprises a base sequence encoding the amino acid sequence of SEQ ID NOS: 30, 31, and 32 in Sequence Listing, respectively (in which one or several amino acids may be substituted, deleted, inserted or added); and polynucleotides in which the region encoding a heavy chain variable region comprises a base sequence encoding the amino acid sequence of SEQ ID NOS: 39, 40, and SFG in Sequence Listing, respectively (in which one or several amino acids may be substituted, deleted, inserted or added) and the region encoding a light chain variable region comprises a base sequence encoding the amino acid sequence of SEQ ID NOS: 36, 37, and 38 in Sequence Listing, respectively (in which one or several amino acids may be substituted, deleted, inserted or added).

[0109]

Other examples of the nucleic acid molecule of the present invention include polynucleotides in which the region encoding a heavy chain comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 5 in Sequence Listing and the region encoding a light chain comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 4 in Sequence Listing; and polynucleotides in which the region encoding a heavy chain comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 7 in Sequence Listing and the region encoding a light chain comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 6 in Sequence Listing.

[0110]

Other examples of the nucleic acid molecule of the present invention include

polynucleotides in which the region encoding a heavy chain comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 9 in Sequence Listing and the region encoding a light chain comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 8 in Sequence Listing.

5 [0111]

Other examples of the nucleic acid molecule of the present invention include polynucleotides in which the region encoding a heavy chain comprises a base sequence encoding the amino acid sequence of any one of SEQ ID NOS: 11 to 18 in Sequence Listing and the region encoding a light chain comprises a base sequence
10 encoding the amino acid sequence of any one of SEQ ID NOS: 19 to 25 in Sequence Listing.

[0112]

Particularly preferred examples of the nucleic acid molecule of the present invention include polynucleotides in which the region encoding a heavy chain
15 comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 15 in Sequence Listing and the region encoding a light chain comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 19 in Sequence Listing.

[0113]

Other examples of the nucleic acid molecule of the present invention include
20 polynucleotides in which the region encoding a heavy chain variable region comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 41 in Sequence Listing and the region encoding a light chain variable region comprises a base sequence encoding the amino acid sequence of SEQ ID NO: 42 in Sequence Listing.

25 [0114]

Specific examples of the nucleic acid molecule of the present invention include polynucleotides in which the region encoding a heavy chain variable region comprises the base sequence of SEQ ID NO: 43 in Sequence Listing and the region

encoding a light chain variable region comprises the base sequence of SEQ ID NO: 44 in Sequence Listing.

[0115]

5 The nucleic acid molecule of the present invention may be polynucleotides which hybridizes under stringent conditions to a complementary strand DNA having the base sequence of SEQ ID NO: 43 in Sequence Listing and polynucleotides which hybridizes under stringent conditions to a complementary strand DNA having the base sequence of SEQ ID NO: 44 in Sequence Listing as long as the nucleic acid molecule of the present invention encodes a monoclonal antibody which has ability
10 to bind to RGMa, does not inhibit the binding between RGMa and neogenin, and neutralizes the neurite outgrowth inhibitory activity of RGMa. Examples of the stringent conditions include a condition of conducting southern hybridization and washing at a salt concentration corresponding to 0.1 x SSC, 0.1% SDS at 68°C.

[0116]

15 The nucleic acid molecule of the present invention may encode all of the constant regions and the variable regions of heavy and light chains, and may encode only the variable regions of heavy and light chains. The base sequence of the constant region of heavy and light chains in the case of encoding all of the constant region and the variable region is preferably those described in Nucleic Acids
20 Research vol.14, p1779, 1986, The Journal of Biological Chemistry vol.257, p1516, 1982 and Cell vol.22, p197, 1980.

[0117]

The nucleic acid molecule of the present invention can be obtained, for example, by the following method. First, total RNA is prepared from cells such as
25 hybridomas using a commercial RNA extraction kit, and cDNA is synthesized with reverse transcriptase using random primers or the like. Next, cDNAs encoding the antibody are amplified by a PCR method using, for primers, oligonucleotides having sequences conserved in the variable regions of known human antibody heavy and

light chain genes, respectively. For the sequence encoding the constant region, it can be obtained by amplifying the known sequence by PCR method. The base sequence of the DNA can be determined by a conventional method, for example by incorporating it into a plasmid for sequencing.

5 Alternatively, a DNA encoding the monoclonal antibody of the present invention can also be obtained by chemically synthesizing a sequence of the variable region or a part thereof and binding it to a sequence comprising the constant region.
[0118]

 The present invention also provides a recombinant vector comprising the
10 nucleic acid molecule of the present invention and a transformant (host cell) comprising the recombinant vector. The recombinant vector may be vectors which can be expressed in prokaryotic cells such as *E. coli* (*Escherichia coli*) (e.g., pBR322, pUC119 or a derivative thereof), and preferably are vectors which can be expressed in eukaryotic cells, and more preferably are vectors which can be expressed in
15 mammalian-derived cells. Examples of the vectors which can be expressed in mammalian-derived cells include plasmid vectors such as pcDNA 3.1 (Invitrogen), pConPlus, pcDM8, pcDNA I/Amp, pcDNA 3.1, pREP4; and viral vectors such as pDON-AI DNA (Takara Bio). The vector may be one vector comprising a heavy chain coding sequence and a light chain coding sequence or may be two vectors of a
20 vector comprising a heavy chain coding sequence and a vector comprising a light chain coding sequence.

[0119]

 The transformant into which the recombinant vector of the present invention is introduced may be a prokaryotic cell such as *Escherichia coli* or *Bacillus subtilis*,
25 preferably a eukaryotic cell, more preferably a mammalian cell. Examples of the mammalian cell include Chinese hamster ovary cells (CHO cells), COS, myeloma, BHK, HeLa, Vero, 293, NS0, Namalwa and YB2/0.

[0120]

The anti-RGMA antibody or antigen-binding fragment thereof obtained can be purified to homogeneity. Separation and purification methods used for ordinary proteins may be used for separation and purification of antibodies and the like. Separation and purification of antibodies can be achieved by appropriately selecting and combining, for example, but not limited to, chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis or isoelectric focusing (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988). Examples of columns used for affinity chromatography include protein A column, protein G column, anti-immunoglobulin antibody-conjugated column and antigen-conjugated column. Examples of the protein A column include Hyper D, POROS and Sepharose F. F. (Amersham Biosciences).

[0121]

Agents for Preventing or Treating Immunological and Neurological Diseases

The RGMA-binding protein, particularly the anti-RGMA antibody or antigen-binding fragment thereof of the present invention neutralizes the neurite outgrowth inhibitory activity of RGMA to promote the repair of neuronal function and thus can be used as an agent for preventing, treating, or preventing the relapse of neurological diseases.

The RGMA-binding protein, particularly the anti-RGMA antibody or antigen-binding fragment thereof of the present invention also neutralizes T-cell activation by RGMA and thus can be used as an agent for preventing, treating, or preventing the relapse of immunological diseases.

[0122]

Examples of the neurological disease include amyotrophic lateral sclerosis, brachial plexus injury, brain damage (including traumatic brain injury), cerebral palsy, Guillain-Barre syndrome, cerebral leukodystrophy, multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple

sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, post-polio syndrome, spina bifida, spinal cord injury, spinal muscular atrophy, spinal neoplasm, transverse myelitis, dementia (including senile dementia, mild cognitive impairment, Alzheimer's disease, dementia associated with Alzheimer's disease), Huntington's disease, tardive dyskinesia, mania, Parkinson's disease, Steele-Richardson syndrome, Down's syndrome, myasthenia gravis, neurotrauma (including optic nerve trauma), vascular amyloidosis, cerebral hemorrhage associated with amyloidosis, brain infarction, cerebritis, acute confusional state, glaucoma, schizophrenia and retinal nerve fiber layer degeneration (including diabetic retinopathy, ischemic optic neuropathy, X-linked retinoschisis, drug-induced optic neuropathy, retinal dystrophy, age-related macular degeneration, eye diseases characterized by optic disc drusen, eye diseases characterized by genetic determinant for photoreceptor degeneration, autosomal recessive cone-rod dystrophy, mitochondrial disorder associated with optic neuropathy). Spinal cord injury and neurotrauma (including optic nerve trauma) are preferred.

[0123]

Examples of the immunological disease include multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, psoriasis, arthritis (including rheumatoid arthritis, osteoarthritis, psoriatic arthritis), Guillain-Barre syndrome, neuro-Behcet disease, pernicious anemia, type I (insulin-dependent) diabetes mellitus, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), Sjogren's syndrome, Goodpasture's syndrome, Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, asthma, pollinosis, atopic dermatitis, glomerulonephritis, myasthenia gravis, Hashimoto's disease, and sarcoidosis. Multiple sclerosis is preferred.

[0124]

The RGMa-binding protein, particularly the anti-RGMa antibody or antigen-

binding fragment thereof of the present invention can be used as an agent for preventing, treating, or preventing the relapse of neurological/immunological diseases, which preferably include spinal cord injury, neurotrauma (including optic nerve trauma) and multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis).

[0125]

As used herein, the term "treating" includes any treatment of diseases in a mammal, particularly a human, and includes inhibiting disease symptoms, that is, inhibiting their progression or eliminating the diseases or symptoms, and alleviating disease symptoms, that is, causing regression of the diseases or symptoms or a delay in the development of the symptoms.

[0126]

"Preventing" includes prevention of onset of the above-described diseases in a mammal, particularly a human.

[0127]

"Preventing the relapse" includes prevention of relapse of the above-described diseases repeating remission and relapse in a mammal, particularly a human.

[0128]

The RGMa-binding protein (anti-RGMa antibody or antigen-binding fragment thereof) of the present invention can be used as a pharmaceutical composition for preventing or treating neurological or immunological diseases.

[0129]

The administration form of the RGMa-binding protein (anti-RGMa antibody or antigen-binding fragment thereof) of the present invention is not particularly limited and can be administered to mammals including humans by any route of oral or parenteral administration (e.g., intravenous, intramuscular, subcutaneous, rectal,

transcutaneous, intracerebral, intraspinal or other topical administration).

[0130]

Dosage forms for oral and parenteral administration and preparation methods thereof are well known to those skilled in the art, and a pharmaceutical
5 composition can be prepared by combining the antibody according to the invention with a pharmaceutically acceptable carrier or the like.

Dosage forms for parenteral administration include injectable preparations (e.g., drip injections, intravenous injections, intramuscular injections, subcutaneous injections, intradermal injections, intracerebral administration preparations, and
10 intraspinal administration preparations), external preparations (e.g., ointments, poultices, and lotions), suppository inhalants, eye drops, ophthalmic ointments, nasal drops, ear drops, and liposomes. In particular, when the antibody according to the present invention is to be directly acted on a central nervous tissue, it can be infused continuously using a medical micropump which is an osmotic pump, or mixed with
15 fibrin glue or the like to prepare a sustained-release preparation and then placed in the affected tissue.

[0131]

For example, injectable preparations are usually prepared by dissolving the antibody in injectable distilled water and, if necessary, a solubilizing agent, a buffer,
20 a pH adjusting agent, an isotonicizing agent, a soothing agent, a preservative, and a stabilizing agent may be added. The injectable preparations may also be lyophilized preparations prepared before use.

[0132]

Dosage forms for oral administration include solid or liquid dosage forms,
25 in particular, tablets, coated tablets, pills, fine granules, granules, powders, capsules, syrups, emulsions, suspensions, injections and troches.

[0133]

The pharmaceutical composition of the present invention may further

contain other therapeutically effective drugs, and if necessary, components such as microbicides, antiphlogistics, vitamins and amino acids may be blended.

[0134]

Pharmacologically acceptable carriers include, for example, excipients,
5 lubricants, binders and disintegrants for solid preparations; and solvents, solubilizing agents, suspending agents, isotonicizing agents, buffers and soothing agents for liquid preparations. If necessary, additives such as usual antiseptics, antioxidants, colorants, sweeteners, adsorbents, and wetting agents may be appropriately used in appropriate amounts.

10 [0135]

The dosage of the antibody according to the present invention can be determined based on various factors such as the route of administration, the type of disease, the degree of symptoms, age, sex, body weight, severity of disease of patients, pharmacological findings such as pharmacokinetic and toxicological
15 characteristics, whether or not a drug delivery system is used, and whether or not it is administered as a part of a combination with other drugs. Usually, 1 to 5,000 $\mu\text{g/day}$, preferably 10 to 2,000 $\mu\text{g/day}$, more preferably 50 to 2,000 $\mu\text{g/day}$ for oral administration or 1 to 5,000 $\mu\text{g/day}$, preferably 5 to 2,000 $\mu\text{g/day}$, more preferably 50 to 2,000 $\mu\text{g/day}$ for injection can be administered per adult (60 kg body weight) in
20 one or several doses. For parenteral administration to the whole body, 10 to 100,000 $\mu\text{g/kg}$, more preferably 100 to 50,000 $\mu\text{g/kg}$, and even more preferably 500 to 20,000 $\mu\text{g/kg}$ per body weight can be administered at an interval of once a day, once a week, once a month, or 1 to 7 times a year. For topical administration using an osmotic pump or the like, in usual, continuous infusion at a rate of 10 to 100,000 $\mu\text{g/day}$,
25 more preferably 100 to 10,000 $\mu\text{g/day}$, still more preferably 500 to 5,000 $\mu\text{g/day}$ per adult (60 kg body weight) is possible.

EXAMPLES

[0136]

The present invention will be described in detail below with reference to Examples, but the present invention is not limited to the aspects of the following Examples.

5 [0137]

Example 1: Preparation of Human RGMa Protein (C-terminal Domain)

A CHO cell expressing a recombinant human RGMa protein in which a histidine tag was fused to the C terminus of Pro 169 to Gly 422 (which refers to the proline residue at position 169 to the glycine residue at position 422 from the N-
10 terminal side, hereinafter similarly described) of the human RGMa protein (SEQ ID NO: 1 in Sequence Listing) was established.

The C-terminal domain of the human RGMa protein contained in the culture supernatant of CHO cells was adsorbed on a nickel column (GE Healthcare, 17-5247-01), and eluted with a 100 mM imidazole solution. By dialysis, the imidazole
15 elution fraction was replaced with Phosphate buffered Saline (PBS) and used as an immunogen.

[0138]

Example 2: Preparation of Mouse Anti-human RGMa Monoclonal Antibody

Ten microgram of the recombinant human RGMa protein prepared in
20 Example 1 was mixed with complete Freund's adjuvant (Sigma) to prepare an emulsion, and a BALB/c mouse (Charles River Japan) was immunized therewith at several subcutaneous sites on the back. Thereafter, immunization was carried out similarly at 1 to 2 week intervals with 10 µg of recombinant human RGMa protein prepared into an emulsion with incomplete Freund's adjuvant (Sigma), and blood was
25 collected after several immunizations. Antibody titer was measured by ELISA described below in which human or mouse RGMa proteins were immobilized. Into individuals which showed an increased antibody titer, 10 µg of human RGMa protein was intravenously administered for boosting, and splenocytes were recovered 2 or 3

days later.

For cell fusion, the spleen cells and mouse myeloma cells (SP2/0, Dainippon Sumitomo Pharma) with half the number of the spleen cells were mixed and centrifuged, and polyethylene glycol (Roche Diagnostics) was added to the resulting precipitate fraction to obtain cell fusions. The cells were then centrifuged and washed twice with D-MEM (Invitrogen). The cells were resuspended in GIT medium (Nippon Pharmaceutical) containing 10% fetal bovine serum (Invitrogen), 1% BM condimed (Roche Diagnostics) and HAT (Sigma-Aldrich) and seeded in each well of a 96-well plate at 5×10^4 myeloma cells/well. The culture supernatant was recovered and screened for antibody-producing cells by the human RGMa protein-immobilized ELISA of Example 3.

Antibody-producing cells obtained by the screening were cloned by the limiting dilution method, and hybridoma cells producing two kinds of monoclonal antibodies (B5.116A3 and B5.70E4) were selected.

Isotypes of both of the monoclonal antibodies determined by using an isotyping kit (Mouse MonoAB ID/SP KIT, ZYMED, 93-6550) were mouse IgG2b for heavy chain and kappa for light chain.

The culture supernatants of the hybridomas were subjected to affinity chromatography using agarose on which anti-mouse IgG antibodies were immobilized (Anti-Mouse IgG-Agarose manufactured by Sigma) to purify the monoclonal antibodies. After the antibody was bound to the column, the column was washed with PBS. Then the antibody was eluted with 10 mM glycine hydrochloride (pH 2.7) and the eluate was neutralized immediately. Thereafter, the neutralized elute was replaced with PBS through an ultrafilter.

[0139]

Example 3: ELISA on Which Human or Mouse RGMa Proteins are Immobilized

Human RGMa protein (R&D systems, 2459-RM) or mouse RGMa protein (R&D systems, 2458-RG) prepared at 2 $\mu\text{g/mL}$ with PBS was dispensed in a 96-well

plate at 50 μ L/well each, and the plate was allowed to stand at room temperature for 1 hour. After removal of the solution, ApplieBlock (Seikagaku Bio-Business, 200150) diluted 5-fold with PBS was dispensed at 200 μ L/well each and the plate was allowed to stand at room temperature for 1 hour to block nonspecific binding.

5 After washing three times with PBST (PBS containing 0.05% Tween 20), samples (e.g., mouse serum, hybridoma culture supernatant, recombinant antibody-expressed culture supernatant described later, or purified antibody) serially diluted with PBS were added at 50 μ L/well each, and the plate was allowed to stand at room temperature for 1 hour. Thereafter, the plate was washed three times with PBST, and

10 then peroxidase-labeled sheep anti-mouse IgG antibody (GE Healthcare, NA9310V) diluted with PBS was dispensed at 50 μ L/well each, and the plate was allowed to stand at room temperature for 1 hour. After washing three times, a peroxidase-coloring kit (Sumitomo Bakelite, ML-1130O) was added and allowed to color develop for a certain period of time, and the absorbance at 492 nm was measured

15 with a plate reader.

[0140]

Example 4: Antibody Epitope Analysis

Epitopes to which the antibodies bind were determined by the peptide scanning method. A total of 83 kinds of peptides were synthesized by fusing the N-

20 terminal side of the amino acid sequences consisting of 11 consecutive residues shifted by 3 residues contained in Arg 172 to Ala 424 of the human RGMa protein (SEQ ID NO: 1 in Sequence Listing) with a spacer sequence (SGSG) with biotinylated N terminus (SEQ ID NO: 46 in Sequence Listing). After immobilizing the peptides on avidin-coated plates, the test antibodies (B5.116A3 and B5.70E4)

25 were allowed to react. Subsequently, a peroxidase-labeled rabbit anti-mouse Ig antibody (Dako, P026002) was allowed to react. After a substrate solution was added and color developed for a certain time, the absorbance was measured with a plate reader.

As a result, B5.116A3 bound to peptides derived from human RGMa of Glu 298 to Gly 311 (two types of peptides: Glu 298 to Asp 308 and Val 301 to Gly 311), Asn 322 to Glu 335 (two types of peptides: Asn 322 to Thr 332 and Ile 325 to Glu 335), and Lys 367 to Ala 377; and B5.70E4 bound to peptides derived from human RGMa of Glu 298 to Gly 311 (two types of peptides: Glu 298 to Asp 308 and Val 301 to Gly 311), Asn 322 to Glu 335 (two types of peptides: Asn 322 to Thr 332 and Ile 325 to Glu 335), and Pro 349 to Thr 359.

[0141]

Example 5: Sequence Analysis and Cloning of Mouse Antibody Gene

Total RNA was extracted from hybridoma cells producing a mouse monoclonal antibody (B5.116A3 or B5.70E4). Using the total RNA as a template, cDNA was synthesized by reverse transcription reaction. Using the cDNA as a template, genes of light chain variable and constant regions, and heavy chain variable and constant regions were amplified by PCR and the DNA sequences were determined. Next, based on the determined sequences of the variable and constant regions, full-length antibody genes were amplified by PCR and cloned. The amino acid sequences encoded by these antibody genes were as follows.

[0142]

(1) B5.116A3 light chain amino acid sequence (SEQ ID NO: 4 in Sequence Listing)

DIQMTQTTSSLSASLGDRVTISCRASQDISSYLNWYQQKPDGTVKLLIYYTSR
LHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQLNTLPWTFGGGKLEI
KRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSRQNG
VLNSWTDQDSKSTYSMSSTLTTLTKDEYERHNSYTCEATHKTSTSPIVKSFN
RNEC

[0143]

(2) B5.116A3 heavy chain amino acid sequence (SEQ ID NO: 5 in Sequence Listing)

EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAE
IRSKANNHATYYAESVKGRFTISRDDSKRSVYLMNNLRAEDTGIYYCTRRD

GAYWGGTGLVTVSAAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESV
 TVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASS
 TTVDDKKLEPSGPISTINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLT
 PKVTCVVVDVSEDDPDVQISWVFNNEVHTAQQTQTHREDYNSTIRVVSTLPI
 5 QHQDWMSGKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRK
 DVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLDSGSGSYFIYSKLNMK
 TSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK

[0144]

(3) B5.70E4 light chain amino acid sequence (SEQ ID NO: 6 in Sequence Listing)

10 DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQRPQGSPKLL
 IYKVSNRFSGVDPDRFSGSGSGTDFTLKISRVEAEDLGLYFCSQSTHVPYTFGG
 GTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGS
 ERQNGVLNSWTDQDSKDYMSSTLTTLTKDEYERHNSYTCEATHKTSTSPI
 VKSFNRNEC

15 [0145]

(4) B5.70E4 heavy chain amino acid sequence (SEQ ID NO: 7 in Sequence Listing)

DVKLQESGPGLVKPSQSLSLTCSVTGYSITTSYYWNWIRQFPGNKLEWMGYI
 SYDGTNNYNPSLKNRISITRDTSKNQFFLRLNSVTTEDTATYYCAGSFGYSQG
 TLVTVSAAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGS
 20 LSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDDKKLE
 PSGPISTINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVV
 DVSEDDPDVQISWVFNNEVHTAQQTQTHREDYNSTIRVVSTLPIQHQDWMS
 GKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLV
 VGFNPGDISVEWTSNGHTEENYKDTAPVLDSGSGSYFIYSKLNMKTSKWEKT
 25 DSFSCNVRHEGLKNYYLKKTISRSPGK

[0146]

Example 6: Preparation of Recombinant Mouse Antibody and Recombinant Rat
 Mouse Chimeric Antibody

Recombinant mouse antibodies of two types of anti-RGMa antibodies B5.116A3 and B5.70E4 derived from hybridomas were prepared (hereinafter referred to as "r116A3" and "r70E4", respectively).

In addition, as a comparative example, recombinant rat mouse chimeric antibody (hereinafter referred to as "r5F9") was prepared by fusing the variable regions of rat antibody 5F9 with the constant regions of mouse antibody (IgG2b κ) (the light chain constant region is Arg 108 to Cys 214 of SEQ ID NO: 4 in Sequence Listing, and the heavy chain constant region is Ala 117 to Lys 452 of SEQ ID NO: 5 of the sequence listing) according to Patent Document 1 (WO2009/106356).

DNA encoding the light and heavy chains of each of the antibodies was inserted into pcDNA 3.3 (Life Technologies) to prepare an expression vector. The expression vector was introduced into HEK293F cells (Life Technologies) using Neofection 293 (ASTEC). The cells were cultured at 37°C under 8% carbon dioxide gas atmosphere for 6 days, and then culture supernatant was recovered. For the purification of the recombinant antibody, the culture supernatant was applied to an affinity column on which Protein A or Protein G was immobilized (GE Healthcare), and antibodies bound to the column were eluted with 10 mM glycine hydrochloride (pH2.8). The eluate was neutralized immediately, and then replaced with PBS.

In the case where refined purity needs to be increased according to purpose of use, the antibodies purified with the Protein A column were purified with a Ceramic Hydroxyapatite Type 1 (CHT) column (BIORAD). Antibodies bound to the CHT column were washed with 10 mM KH₂PO₄ (pH6.5) and then eluted with 20 mM KH₂PO₄ (pH6.5), 0.5 M NaCl. Eluted fractions were collected and then replaced with PBS.

[0147]

Example 7: Binding Assay on RGMa Protein Expressing Cells

A vector expressing full-length human RGMa protein (Met 1 to Cys 450 of SEQ ID NO: 1 in Sequence Listing), human RGMa protein C-terminal domain (Pro

169 to Cys 450 of SEQ ID NO: 1 in Sequence Listing), full-length mouse RGMa protein (Met 1 to Trp 454 of SEQ ID NO: 2 in Sequence Listing), or rat RGMa protein C-terminal domain (Pro 170 to Trp 449 of SEQ ID NO: 3 in Sequence Listing) was introduced into CHO or HEK 293 cells to prepare antigen-expressing
 5 cells.

In RGMa proteins, the C-terminal peptide is processed during GPI anchor addition reaction. Mouse and rat RGMa proteins are both cleaved at Ala 427 and the C-terminal peptide is removed. Therefore, the amino acid sequences of the full-length protein and the C-terminal domain expressed on a cell via a GPI anchor are
 10 the same in mouse and rat.

Test antibodies (r116A3 and r70E4) and r5F9 (Comparative Example) with a final concentration of 10 µg/mL were reacted with the above-described antigen-expressing cells and then the cells were washed with PBS containing 0.1% bovine serum albumin and 0.05% NaN₃. FITC-labeled anti-mouse immunoglobulin
 15 antibody (DAKO) was allowed to react and the cells were washed. Fluorescence was measured with flow cytometry (FACSCalibur manufactured by Beckton Dickinson), and the binding properties of the test antibodies to the antigen-expressing cells were evaluated (Table 1).

As a result, r116A3 and r70E4 were found to bind to the C-terminal domain
 20 of human and rat RGMa proteins, unlike r5F9. RGMa protein has neurite outgrowth inhibitory effect even in the C-terminal domain alone, and r116A3 and r70E4 inhibit both the full-length RGMa protein and the C-terminal domain.

[0148]

Table 1: Evaluation of binding of various recombinant anti-RGMa antibodies to
 25 antigen-expressing cells*

	Full-length human RGMa	Human RGMa C-terminal domain	Full-length mouse RGMa	Rat RGMa C-terminal domain
r116A3	++	++	++	++
r70E4	++	++	+	++

r5F9	++	-	++	-
------	----	---	----	---

*; ++ Strongly bind

+ Weakly bind

- Not bind

5 [0149]

Example 8: Determination of Dissociation Constant for RGMa Protein

The affinity of the test antibodies (r116A3 and r70E4) and r5F9 (Comparative Example) for RGMa protein were measured by the surface plasmon resonance (SPR) method using Proteon XPR36 (Bio-Rad).

10 Human RGMa protein (R&D Systems, 2459-RM), the C-terminal domain of human RGMa protein (prepared in Example 1) or mouse RGMa protein (R&D Systems, 2458-RG) diluted to 10 µg/mL with 10 mM acetate buffer (pH4.5) was immobilized on a GLC sensor chip by amine coupling method. The serially diluted test antibodies were applied as analytes at a flow rate of 100 µL/min for 60 seconds
15 to determine the dissociation constant (Kd value).

As shown in Table 2, r116A3 and r70E4 also bound to the C-terminal domain of human RGMa protein, but r5F9 did not. R116A3 bound to human RGMa protein 32 times stronger than r5F9 and to mouse RGMa protein 44 times stronger than r5F9.

20 [0150]

Table 2: Affinity of anti-RGMa monoclonal antibody

Antibody	Dissociation Constant (Kd value, nM)		
	Human RGMa	Human RGMa C-terminal domain	Mouse RGMa
r116A3	0.0487	0.0568	0.201
r70E4	2.43	1.12	174
r5F9 (Comparative Example)	1.59	not bind	8.98

[0151]

Example 9: RGMa-Neogenin Binding Inhibition Assay

The extracellular domain (Ala 34 to Leu 1105) of the recombinant human neogenin protein (SEQ ID NO: 10 in Sequence Listing) was purified. A CHO cell
5 line expressing human Neogenin protein extracellular domain was established. A histidine tag was fused to the C-terminus. From the culture supernatant of CHO cells, the extracellular domain was adsorbed on a nickel column (GE Healthcare, 17-5247-01), and then eluted with a 100 mM imidazole solution. By dialysis, the imidazole elution fraction was replaced with PBS.

10 Human RGMa protein (R&D systems, 2459-RM) was labeled with biotin using ChromaLink Biotin Labeling Kit (Solulink). Equal amounts of the biotin-labeled human RGMa protein adjusted to 2 µg/mL and the test antibodies (r116A3 and r70E4) subjected to 2-fold serial dilution were mixed and allowed to react at room temperature for 2 hours to prepare a mixed solution.

15 At the same time, 50 µL/well of the human neogenin protein extracellular domain adjusted to 2 µg/mL with PBS was added to a 96-well plate, and the plate was allowed to stand at room temperature for 1 hour to prepare a neogenin-immobilized plate. After removal of the solution, 2.5% bovine serum albumin solution was added and the plate was left to stand for 1 hour to block nonspecific
20 binding. To the neogenin-immobilized plate, the above-described mixed solution was added at 50 µL/well, and the plate was allowed to stand at room temperature for 1 hour. Then, a washing operation was performed, and peroxidase-labeled Avidin (VECTASTAIN ABC system, manufactured by Vector Laboratories) was added, and the plate was allowed to stand at room temperature for 1 hour. A washing operation
25 was then performed, a substrate solution was added, color development was carried out for a certain period of time, and the absorbance was measured with a plate reader. The absorbance ratio in the absence of the antibody was plotted as 1, and the concentration-dependent RGMa-neogenin binding inhibition by the antibody was

evaluated (Fig. 1).

As a result, unlike anti-human RGMa polyclonal antibody (R&D Systems, AF2459) and r5F9, r116A3 and r70E4 did not inhibit RGMa-neogenin binding. [0152]

5 Example 10: RGMa-BMP2 Binding Inhibition Assay

Human RGMa protein (R&D systems, 2459-RM) adjusted to 2 µg/mL with PBS was added to a 96-well plate at 50 µL/well each, and the plate was allowed to stand at room temperature for 1 hour. A 2.5% bovine serum albumin solution was added and the mixture was allowed to stand for 1 hour to block nonspecific binding, thereby preparing RGMa protein-immobilized plate. The test antibodies (B5.116A3 and B5.70E4) serially diluted to 0.01 to 10 µg/mL were added to the RGMa protein-immobilized plate and the plate was allowed to stand at room temperature for 1 hour. Then, a washing operation was performed, and human BMP2 protein (R&D systems, 355-BM) diluted to 0.5 µg/mL was added and the plate was left to stand at room temperature for 1 hour. 15

A biotin-labeled anti-BMP2 antibody was allowed to react, and further added with peroxidase-labeled Avidin (VECTASTAIN ABC system, manufactured by Vector Laboratories) and a substrate solution were added, color development was carried out for a certain period of time, and the absorbance was measured with a plate reader (Fig. 2). 20

As a result, in particular, the anti-RGMa antibody (B5.116A3) weakly inhibited the binding of RGMa-BMP2 in a concentration-dependent manner (Absorbance: 0.45 at 0.01 µg/mL, 0.4 at 0.1 µg/mL, 0.32 at 1 µg/mL, and 0.1 at 10 µg/mL). 25 [0153]

Example 11: Design of Humanized Antibody

Humanization of the mouse monoclonal antibody B5.116A3 was carried out by complementarity determining region (CDR) grafting according to the method by

Winter et al. described in Patent No. 2912618.

First, 3D homology models of the light and heavy chain variable regions of the mouse monoclonal antibody B5.116A3 were prepared and amino acid residues within the framework (FW) region, located near CDR were identified. FWs of human antibodies in which these amino acids are maintained as many as possible were selected, CDRs of the mouse antibody were grafted thereto, and thus designing a humanized antibody. In the designed humanized antibody sequence, the heavy chain is described as HA (SEQ ID NO: 11 in Sequence Listing) and the light chain is described as KA (SEQ ID NO: 19 in Sequence Listing). In addition, a plurality of humanized antibody sequences were designed by introducing additional mutations into amino acids within FWs involved in structural stability of the variable region (A total of 8 heavy chains ranging from HB to HH including HA and a total of 7 light chains ranging from KB to KG including KA).

[0154]

Table 3: Designed humanized antibody sequences

Heavy Chain		SEQ ID NO in the sequence listing
HA	Sequence in which CDRs of mouse antibody B5.116A3 are grafted to FWs of human antibody	11
HB	HA sequence with substitution of Ala 81 by Val and Lys 89 by Arg	12
HC	HA sequence with substitution of Ala 81 by Val	13
HD	HA sequence with substitution of Lys 89 by Arg	14
HE	HA sequence with substitution of Ala 81 by Val, Lys 89 by Arg, and Phe 37 by Val	15
HF	HA sequence with substitution of Leu 95 by Val	16
HG	HA sequence with substitution of Phe 37 by Val	17
HH	HA sequence with substitution of Phe 37 by Val, and Leu 95 by Val	18
Light Chain		
KA	Sequence in which CDRs of mouse antibody B5.116A3 are grafted to FWs of human antibody	19
KB	KA sequence with substitution of Phe 71 by Tyr	20
KC	KA sequence with substitution of Phe 71 by Tyr, and Phe 44 by Val	21

KD	KA sequence with substitution of Ser 85 by Thr	22
KE	KA sequence with substitution of Pro 44 by Val	23
KF	KA sequence with substitution of Pro 44 by Val, and Ser 85 by Thr	24
KG	KA sequence with substitution of Phe 71 by Tyr, Pro 44 by Val, and Ser 85 by Thr	25

[0155]

Example 12: Preparation of Recombinant Mouse Human Chimeric Antibody and Recombinant Humanized Antibody

- 5 (1) Recombinant mouse human chimeric anti-RGMA antibody 116A3 (r116A3C) having the following amino acid sequences was prepared according to Example 6.

[0156]

Light chain (SEQ ID NO: 8 in Sequence Listing)

10 DIQMTQTTSSLSASLGDRVTISCRASQDISSYLNWYQQKPDGTVKLLIYYTSR
LHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQLNTLPWTFGGGKLEI
KRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF
NRGEC

15 [0157]

Heavy chain (SEQ ID NO: 9 in Sequence Listing)

EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAE
IRSKANNHATYYAESVKGRFTISRDDSKRSVYLQMNNLRAEDTGIYYCTRDR
GAYWGQGTLLTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
20 VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0158]

(2) A total of 20 humanized anti-RGMA antibodies comprising the following combinations of heavy and light chains were prepared according to Example 6.

5 [0159]

Heavy chain/light chain combinations;

HA/KA, HA/KB, HA/KC, HA/KG, HB/KC, HC/KA, HC/KB, HD/KA, HD/KB,
HD/KC, HD/KD, HE/KA, HF/KA, HF/KF, HF/KG, HG/KD, HG/KH, HH/KA,
HH/KD, HH/KF

10 [0160]

(3) A recombinant humanized anti-RGMA antibody (hereinafter referred to as rH5F9) was prepared according to Example 6 (Comparative Example).

The variable region of the humanized anti-RGMA monoclonal antibody h5F9 described in Patent Document 1 (WO2009/106356) (the light chain is seq

15 ID_53 of Patent Document 1, and the heavy chain is seq ID_50 of Patent Document 1) was ligated with the human antibody constant region (the light chain is Arg 108 to Cys 214 of SEQ ID NO: 26 in Sequence Listing, and heavy chain is Ala 117 to Lys 446 of SEQ ID NO: 27 in Sequence Listing).

[0161]

20 Example 13: Thermal Stability Test for Antibody

Twenty μ L aliquots of the culture supernatant in which the recombinant antibody described in Example 12 was expressed were collected and heat-treated for 10 minutes at 8 temperature points of 40, 45, 50, 55, 60, 65, 70 and 75°C, respectively, using a thermal cycler (Takara bio, TP 600). The culture supernatant
25 was diluted with PBS so that the final concentration of the antibody was 125 ng/mL. Thereafter, the culture supernatant was subjected to ELISA on which human RGMA proteins are immobilized described in Example 3 to evaluate the antigen binding property of the antibody (Fig. 3).

As a result, a humanized antibody comprising a combination of heavy chain HE and light chain KA (hereinafter referred to as "rH116A3"), and a mouse human chimeric antibody (r116A3C) showed better thermal stability than the humanized antibody (rH5F9). Hereinafter, the humanized antibody comprising this combination
 5 of HE/KA is described as rH116A3.

When the heat treatment was not performed, the mouse human chimeric antibody (r116A3C) and the humanized antibody (rH116A3) showed equivalent antigen binding properties, and there was no decrease in antigen binding property associated with humanization.

10 [0162]

Example 14: Establishment of a CHO Stable Cell Line Producing Humanized Anti-RGMA Antibody (rH116A3)

A CHO stable cell line producing humanized anti-RGMA antibody (rH116A3) was established using Lonza GS Xceed system (Lonza). A pXC double
 15 gene vector comprising the light chain coding sequence (SEQ ID NO: 44 in Sequence Listing) and the heavy chain coding sequence (SEQ ID NO: 43 in Sequence Listing) of the humanized anti-RGMA antibody (rH116A3) was introduced into a CHOK1SV GS knock out parent cell line, and a pool of transformed cells was obtained under methionine sulfoximine (MSX) selection. After separating into
 20 single cells by flow cytometry, antibody production amount in culture supernatant, cell proliferation and the like were evaluated, and a CHO stable cell line was obtained.

[0163]

Example 15: Neurite Outgrowth Assay

25 A cerebellum was excised from a neonatal rat (P7), suspended in a trypsin solution (0.25% trypsin solution in PBS containing 0.2% DNase) and digested at 37 °C for 10 to 15 minutes. Next, DMEM medium containing 10% fetal bovine serum was added and the mixture was centrifuged. The cells were resuspended in the same

medium and centrifuged, and the same procedure was repeated twice to wash the cells. Further, this cell suspension was filtered through a 70 μm cell strainer and centrifuged, and the precipitated fraction was resuspended in the same medium. B27 supplement (GIBCO) was added to the cell suspension to prepare neonatal rat cerebellar granule cells.

Next, the neonatal rat cerebellar granule cells were seeded on a cell culture plate and cultured at 37 °C for 1 day.

Recombinant RGMa protein (R&D systems, 2459-RM) with a final concentration of 2 $\mu\text{g/mL}$ was added and the cells were cultured at 37 °C for 2 days.

The neurite length was measured by microscopy. As shown in Fig. 4, the addition of RGMa resulted in neurite length changes from 37 μm to 26 μm in the experiment on the left figure and from 38 μm to 27 μm in the right figure, thus inhibiting neurite outgrowth. Although addition of only the test antibody (B5.116A3 or B5.70E4) at a final concentration of 10 $\mu\text{g/mL}$ did not change the neurite length, simultaneous addition of recombinant RGMa protein and the test antibody induced neurite outgrowth to the same extent as a control (no RGMa added), which indicate neutralizing effect of the antibody against RGMa protein.

[0164]

Example 16: Efficacy Test Using a Rat Spinal Cord Injury Model.

A Wistar rat (female, 8 weeks old, weighing about 200 g) anesthetized by aspiration of halothane (Takeda Pharmaceutical) was subjected to a laminectomy of the anterior and posterior vertebrae around the spinal level T9 (T8 to T10), and the spinal cord was exposed. In the case of evaluation using spinal cord crush model, pressure of 200 kdyn was applied to the exposed spinal cord using IH impactor (Precision System).

Immediately after damaging the spinal cord as described above, an osmotic minipump filled with 400 $\mu\text{g/mL}$ of the test antibody (r116A3 or r70E4) or a control mouse antibody (mo-IgG2b κ) (200 μL volume, 0.5 $\mu\text{L}/\text{hour}$, 14 Day delivery) (Alzet,

model 2002) was placed under the skin of the back of the rat. The tip of a silicon tube connected to the outlet of the osmotic mini pump was placed under the dura at the site of spinal cord injury. The tube was sewn and fixed to the spinous processes on the right lower limb side of the laminectomized site, the muscle and skin layers were sutured, and the rat was raised.

The motor function of spinal cord injury model rat was evaluated using Basso-Beattie-Bresnahan (BBB) score (Basso, D.M., Beattie, M.S., & Bresnahan, J.C., A sensitive and reliable locomotor rating scale for open field testing in rats. *J Neurotrauma* 12, 1-21 (1995)) at 0, 1, 3 and 7 days after injury, and every week thereafter for up to 8 weeks. As a result, as shown in Fig. 5(A), r116A3 or r70E4 significantly improved the BBB score 4 or 3 weeks after administration, respectively, compared to the control antibody (mo-IgG2bκ) ($p < 0.05$, Student's t-test).

In the case of evaluation using a spinal cord hemisection model, the dorsal side of the exposed spinal cord was cut to a depth of 1.8 mm to 2.0 mm. In the same manner as above, the test antibody (B5.116A3) or the control mouse antibody (mo-IgG2bκ) was administered using osmotic minipump and evaluated using BBB score at 0, 1, 3 and 7 days after injury, and every week thereafter for up to 10 weeks. As shown in Fig. 5(B), B5.116A3 significantly improved the BBB score 4 weeks after administration compared to the control antibody (mo-IgG2bκ) ($p < 0.01$, Student's t-test).

[0165]

Example 17: Efficacy Test Using Mouse Model with Multiple Sclerosis

PLP₁₃₉₋₁₅₁ peptide (HSLGKWLGHDPKF: SEQ ID NO: 45 in Sequence Listing, Peptide Institute) was dissolved in physiological saline (Otsuka Pharmaceutical Factory) and mixed with incomplete Freund's adjuvant (Sigma) to which dead tubercle bacillus H37 Ra (Difco Laboratories) was added to prepare an emulsion. SJL/JorllcoCrj (SJL/J) mouse (Charles River Japan) was immunized subcutaneously in the back with the PLP₁₃₉₋₁₅₁ peptide at 50 µg/head, and EAE score

and body weight change were evaluated (H. Kataoka, K Sugahara, K. Shimano, K. Teshima, M. Koyama, A. Fukunari and K. Chiba. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cellular & Molecular Immunology 6, 439-448, 2005.)

5 (Fig. 6).

Test antibody (B5.116A3) diluted in physiological saline was intraperitoneally administered at 20 mg/kg each at 7 and 10 days or 18 and 21 days after the immunization with PLP₁₃₉₋₁₅₁ peptide.

As a result, as shown in Fig. 6, compared with the control antibody (mo-
10 IgG2bk), the anti-RGMA mouse monoclonal antibody (B5.116A3) inhibited the deterioration of EAE score by administration before onset (upper part of Fig. 6) and showed relapse prevention effect by administration after onset (lower part of Fig. 6).
[0166]

Example 18: Immunogenicity Test of Antibody

15 Undifferentiated dendritic cells contained in peripheral blood derived from 51 healthy donors were matured by granulocyte-monocyte colony-stimulating factor (GM-CSF) and Interleukin-4 stimulations. The test antibody (rH116A3) at a final concentration of 50 µg/mL was added to the mature dendritic cells and the cells were cultured for 4, 5 days to allow the antibody to be taken up into the dendritic cells.
20 Peripheral blood CD4⁺ T cells (helper T cells) derived from the same donor were mixed with the dendritic cells, and co-cultured for another week, and then the proliferation of T cells was measured by flow cytometry. Using the T cell proliferation activity of the test antibody as an index, the immunogenicity risk in human was evaluated. As a result, T cell proliferation was observed in 4 (7.8%) out
25 of 51 donors, and thus the immunogenicity risk was low.

CLAIMS

1. An isolated RGMa-binding protein, which does not inhibit binding between Repulsive Guidance Molecule a (RGMa) and neogenin but neutralizes the neurite
5 outgrowth inhibiting activity of RGMa.
2. The RGMa-binding protein according to claim 1, which binds to human, rat and/or mouse RGMa.
- 10 3. The RGMa-binding protein according to claim 1 or 2, which binds to peptides of EEVVNAVEDWDSQG (SEQ ID NO: 26 in Sequence Listing), NQQIDFQAFHTNAE (SEQ ID NO: 27 in Sequence Listing), PTAPETFPYET (SEQ ID NO: 28 in Sequence Listing), and/or KLPVEDLYYQA (SEQ ID NO: 29 in Sequence Listing).
15
4. The RGMa-binding protein according to any one of claims 1 to 3, which binds to peptides of SEQ ID NOS: 26 and 27 in Sequence Listing.
5. The RGMa-binding protein according to any one of claims 1 to 4, which
20 binds to peptides of SEQ ID NOS: 26, 27 and 28 in Sequence Listing.
6. The RGMa-binding protein according to any one of claims 1 to 4, which binds to peptides of SEQ ID NOS: 26, 27 and 29 in Sequence Listing.
- 25 7. The RGMa-binding protein according to any one of claims 1 to 6, wherein the RGMa-binding protein is a human antibody, a humanized antibody or a chimeric antibody, or an antigen-binding fragment thereof.

8. A nucleic acid molecule coding for the protein portion of the RGMa-binding protein according to any one of claims 1 to 7.
9. A recombinant vector comprising the nucleic acid molecule according to
5 claim 8.
10. A host cell containing the recombinant vector according to claim 9.
11. A method for producing the RGMa-binding protein according to any one of
10 claims 1 to 7, the method comprising a step of culturing the host cell according to claim 10.
12. A pharmaceutical composition comprising the RGMa-binding protein according to any one of claims 1 to 7.
15
13. The pharmaceutical composition according to claim 12 for use in preventing, treating, or preventing the relapse of neurological or immunological diseases.
- 20 14. The pharmaceutical composition according to claim 13, wherein the neurological diseases are selected from the group consisting of amyotrophic lateral sclerosis, brachial plexus injury, brain damage (including traumatic brain injury), cerebral palsy, Guillain-Barre syndrome, cerebral leukodystrophy, multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple
25 sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, post-polio syndrome, spina bifida, spinal cord injury, spinal muscular atrophy, spinal neoplasm, transverse myelitis, dementia (including senile dementia, mild cognitive impairment, Alzheimer's disease, dementia associated with Alzheimer's disease), Huntington's

disease, tardive dyskinesia, mania, Parkinson's disease, Steele-Richardson syndrome, Down's syndrome, myasthenia gravis, neurotrauma (including optic nerve trauma), vascular amyloidosis, cerebral hemorrhage associated with amyloidosis, brain infarction, cerebritis, acute confusional state, glaucoma, schizophrenia and retinal nerve fiber layer degeneration (including diabetic retinopathy, ischemic optic neuropathy, X-linked retinoschisis, drug-induced optic neuropathy, retinal dystrophy, age-related macular degeneration, eye diseases characterized by optic disc drusen, eye diseases characterized by genetic determinant for photoreceptor degeneration, autosomal recessive cone-rod dystrophy, mitochondrial disorder associated with optic neuropathy).

15. The pharmaceutical composition according to claim 13, wherein the immunological diseases are selected from the group consisting of multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, psoriasis, arthritis (including rheumatoid arthritis, osteoarthritis, psoriatic arthritis), Guillain-Barre syndrome, neuro-Behcet disease, pernicious anemia, type I (insulin-dependent) diabetes mellitus, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), Sjogren's syndrome, Goodpasture's syndrome, Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, asthma, pollinosis, atopic dermatitis, glomerulonephritis, myasthenia gravis, Hashimoto's disease, and sarcoidosis.

16. The pharmaceutical composition according to claim 13, wherein the neurological or immunological diseases are selected from the group consisting of spinal cord injury, neurotrauma (including optic nerve trauma) and multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis).

17. An isolated anti-RGMa antibody, or an antigen-binding fragment thereof,
 wherein the amino acid sequence of each of the light chain complementarity
 determining region 1 (LCDR1), the light chain complementarity determining region
 2 (LCDR2), the light chain complementarity determining region 3 (LCDR3), the
 heavy chain complementarity determining region 1 (HCDR1), the heavy chain
 complementarity determining region 2 (HCDR2) and the heavy chain
 complementarity determining region 3 (HCDR3) comprises the following:
 LCDR1: RASQDISSYLN (SEQ ID NO: 30 in Sequence Listing),
 LCDR2: YTSRLHS (SEQ ID NO: 31 in Sequence Listing),
 LCDR3: QQLNTLP (SEQ ID NO: 32 in Sequence Listing),
 HCDR1: DAWMD (SEQ ID NO: 33 in Sequence Listing),
 HCDR2: EIRSKANNHATYYAESVKG (SEQ ID NO: 34 in Sequence Listing) and
 HCDR3: RDGAY (SEQ ID NO: 35 in Sequence Listing);
 or
 LCDR1: RSSQSLVHSNGNTYLH (SEQ ID NO: 36 in Sequence Listing)
 LCDR2: KVSNRFS (SEQ ID NO: 37 in Sequence Listing)
 LCDR3: SQSTHVP (SEQ ID NO: 38 in Sequence Listing)
 HCDR1: TSYYWN (SEQ ID NO: 39 in Sequence Listing)
 HCDR2: YISYDGTNNYNPSLKN (SEQ ID NO: 40 in Sequence Listing) and
 HCDR3: SFG, and
 wherein in each of the CDR sequences one or several amino acids may be
 substituted, deleted, and/or added.

18. The anti-RGMa antibody or an antigen-binding fragment thereof according
 to claim 17,

wherein the heavy chain variable region (VH) comprises the following:

VH:

EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAE
IRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRD
GAYWGKGTTVTVSS (SEQ ID NO: 41 in Sequence Listing) or an amino acid

sequence having an identity of at least 90% with said amino acid sequence; and

5 wherein the light chainvariable region (VL) comprises the following:

VL:

DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSR
LHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTPWTFGGGTKVEM
E (SEQ ID NO: 42 in Sequence Listing) or an amino acid sequence having an

10 identity of at least 90% with said amino acid sequence.

19. The anti-RGMa antibody or an antigen-binding fragment thereof according
to claim 17 or 18, wherein the anti-RGMa antibody is a humanized antibody.

15 20. The anti-RGMa antibody or an antigen-binding fragment thereof according
to any one of claims 17 to 19, wherein the anti-RGMa antibody comprises constant
regions of human IgG.

21. An RGMa-binding protein, which competes with the anti-RGMa antibody
20 according to claim 17 or 18 for binding to RGMa.

22. A nucleic acid molecule coding for the protein portion of the anti-RGMa
antibody or an antigen-binding fragment thereof according to any one of claims 17 to
20.

25

23. The nucleic acid molecule according to claim 22, wherein the nucleotide
sequences coding for the VH and VL amino acid sequences each is a nucleotide
sequence comprising:

VH:

gaagtgcagctggtggaatctggcggcggactggtgcagcctggcagatccctgagactgtcctgtaccgcctccggct
 tcaccttctccgacgcctggatggattgggtgcgacaggctcctggcaagggcctggaatgggtggccgagatccggtc
 caaggccaacaaccacgccacctactacgccgagtctgtgaagggccggttcaccatctccgggacgactccaagtcc
 5 atcgtgtacctgcagatgaactccctgcggaccgaggacaccgccctgtactactgcaccagaagggacggcgcctact
 ggggcaagggcaccacagtgcagctgtcctcc (SEQ ID NO: 43 in Sequence Listing), and

VL:

gacatccagatgaccagtcctccctcctccgtgtctgcttccgtgggcgacagagtgaccatcacctgtcgggcctccca
 ggacatctcctctacctaactggtatcagcagaagcccggaaggccccaagctgctgatctactacacctccggc
 10 tgcactccggcgtgccctctagattttccggctctggctccggcaccgactttaccctgaccatctccagcctgcagcccc
 aggacttcgcctcctacttctgtcagcagctgaacaccctgcctggacctttggcggaggcaccaaggtggaaatggaa
 (SEQ ID NO: 44 in Sequence Listing).

24. A recombinant vector comprising the nucleic acid molecule according to
 15 claim 22 or 23.

25. A host cell containing the recombinant vector according to claim 24.

26. A method for producing the anti-RGMa antibody or an antigen-binding
 20 fragment thereof according to any one of claims 17 to 20, the method comprising a
 step of culturing the host cell according to claim 25.

27. A pharmaceutical composition comprising the anti-RGMa antibody or an
 antigen-binding fragment thereof according to any one of claims 17 to 20.

25

28. The pharmaceutical composition according to claim 27 for use in
 preventing, treating, or preventing the relapse of neurological or immunological
 diseases.

29. The pharmaceutical composition according to claim 28, wherein the neurological diseases are selected from the group consisting of amyotrophic lateral sclerosis, brachial plexus injury, brain damage (including traumatic brain injury), cerebral palsy, Guillain-Barre syndrome, cerebral leukodystrophy, multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, post-polio syndrome, spina bifida, spinal cord injury, spinal muscular atrophy, spinal neoplasm, transverse myelitis, dementia (including senile dementia, mild cognitive impairment, Alzheimer's disease, dementia associated with Alzheimer's disease), Huntington's disease, tardive dyskinesia, mania, Parkinson's disease, Steele-Richardson syndrome, Down's syndrome, myasthenia gravis, neurotrauma (including optic nerve trauma), vascular amyloidosis, cerebral hemorrhage associated with amyloidosis, brain infarction, cerebritis, acute confusional state, glaucoma, schizophrenia and retinal nerve fiber layer degeneration (including diabetic retinopathy, ischemic optic neuropathy, X-linked retinoschisis, drug-induced optic neuropathy, retinal dystrophy, age-related macular degeneration, eye diseases characterized by optic disc drusen, eye diseases characterized by genetic determinant for photoreceptor degeneration, autosomal recessive cone-rod dystrophy, mitochondrial disorder associated with optic neuropathy).

30. The pharmaceutical composition according to claim 28, wherein the immunological diseases are selected from the group consisting of multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis), neuromyelitis optica, psoriasis, arthritis (including rheumatoid arthritis, osteoarthritis, psoriatic arthritis), Guillain-Barre syndrome, neuro-Behcet disease, pernicious anemia, type I (insulin-dependent) diabetes mellitus, systemic lupus erythematosus (SLE), inflammatory

bowel disease (IBD), Sjogren's syndrome, Goodpasture's syndrome, Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, asthma, pollinosis, atopic dermatitis, glomerulonephritis, myasthenia gravis, Hashimoto's disease, and sarcoidosis.

5

31. The pharmaceutical composition according to claim 28, wherein the neurological or immunological diseases are selected from the group consisting of spinal cord injury, neurotrauma (including optic nerve trauma), multiple sclerosis (including relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis).

10

JPOXMLDOC01-seq1.app
SEQUENCE LISTING

<110> Mitsubishi Tanabe Pharma Corporation
Osaka University
National University Corporation Chiba University

<120> RGMa binding protein and its use

<130> A16005-16140

<150> JP2015-091095

<151> 2015-04-28

<160> 46

<170> PatentIn version 3.5

<210> 1

<211> 450

<212> PRT

<213> Homo sapiens

<400> 1

```

Met Gln Pro Pro Arg Glu Arg Leu Val Val Thr Gly Arg Ala Gly Trp
1      5      10      15
Met Gly Met Gly Arg Gly Ala Gly Arg Ser Ala Leu Gly Phe Trp Pro
      20      25      30
Thr Leu Ala Phe Leu Leu Cys Ser Phe Pro Ala Ala Thr Ser Pro Cys
      35      40      45
Lys Ile Leu Lys Cys Asn Ser Glu Phe Trp Ser Ala Thr Ser Gly Ser
      50      55      60
His Ala Pro Ala Ser Asp Thr Pro Glu Phe Cys Ala Ala Leu Arg
65      70      75      80
Ser Tyr Ala Leu Cys Thr Arg Arg Thr Ala Arg Thr Cys Arg Gly Asp
      85      90      95
Leu Ala Tyr His Ser Ala Val His Gly Ile Glu Asp Leu Met Ser Gln
      100      105      110
His Asn Cys Ser Lys Asp Gly Pro Thr Ser Gln Pro Arg Leu Arg Thr
      115      120      125
Leu Pro Pro Ala Gly Asp Ser Gln Glu Arg Ser Asp Ser Pro Glu Ile
      130      135      140
Cys His Tyr Glu Lys Ser Phe His Lys His Ser Ala Thr Pro Asn Tyr
145      150      155      160
Thr His Cys Gly Leu Phe Gly Asp Pro His Leu Arg Thr Phe Thr Asp
      165      170      175
Arg Phe Gln Thr Cys Lys Val Gln Gly Ala Trp Pro Leu Ile Asp Asn
      180      185      190
Asn Tyr Leu Asn Val Gln Val Thr Asn Thr Pro Val Leu Pro Gly Ser
      195      200      205
Ala Ala Thr Ala Thr Ser Lys Leu Thr Ile Ile Phe Lys Asn Phe Gln
      210      215      220
Glu Cys Val Asp Gln Lys Val Tyr Gln Ala Glu Met Asp Glu Leu Pro
225      230      235      240
Ala Ala Phe Val Asp Gly Ser Lys Asn Gly Gly Asp Lys His Gly Ala
      245      250      255
Asn Ser Leu Lys Ile Thr Glu Lys Val Ser Gly Gln His Val Glu Ile
      260      265      270
Gln Ala Lys Tyr Ile Gly Thr Thr Ile Val Val Arg Gln Val Gly Arg
      275      280      285
Tyr Leu Thr Phe Ala Val Arg Met Pro Glu Glu Val Val Asn Ala Val
      290      295      300
Glu Asp Trp Asp Ser Gln Gly Leu Tyr Leu Cys Leu Arg Gly Cys Pro
305      310      315      320
Leu Asn Gln Gln Ile Asp Phe Gln Ala Phe His Thr Asn Ala Glu Gly
      325      330      335
Thr Gly Ala Arg Leu Ala Ala Ala Ser Pro Ala Pro Thr Ala Pro
      340      345      350
Glu Thr Phe Pro Tyr Glu Thr Ala Val Ala Lys Cys Lys Glu Lys Leu

```

JPOXMLDOC01-seq1.app

Pro Val 355 Glu Asp Leu Tyr Tyr 360 Gln Ala Cys Val Phe 365 Leu Leu Thr
 370 Thr Gly Asp Val Asn Phe 375 Leu Ala Ala Tyr Tyr 380 Ala Leu Glu Asp
 385 Val Lys Met Leu His 390 Ser Asn Lys Asp Lys 395 Leu His Leu Tyr Asp Arg
 400 Thr Arg Asp Leu 405 Pro Gly Arg Ala 410 Ala Gly Leu Pro Leu Ala Pro
 420 Arg Pro Leu Leu Gly Ala Leu Val 425 Pro Leu Leu Ala Leu 430 Leu Pro Val
 435 Phe Cys 440 445 450

<210> 2
 <211> 454
 <212> PRT
 <213> Mus musculus

<400> 2
 Met Gln Pro Pro Arg Glu Arg Leu Val Val Thr Gly Arg Ala Gly Trp
 1 5 10 15
 Met Gly Met Gly Arg Gly Ala Gly Arg Ser Ala Leu Gly Leu Trp Pro
 20 25 30
 Thr Leu Ala Phe Leu Leu Cys Ser Phe Pro Ala Ala Ile Ser Pro Cys
 35 40 45
 Lys Ile Leu Lys Cys Asn Ser Glu Phe Trp Ser Ala Thr Ser Ser Gly
 50 55 60
 Ser His Ala Pro Ala Ser Asp Asp Val Pro Glu Phe Cys Ala Ala Leu
 65 70 75 80
 Arg Thr Tyr Ala Leu Cys Thr Arg Arg Thr Ala Arg Thr Cys Arg Gly
 85 90 95
 Asp Leu Ala Tyr His Ser Ala Val His Gly Ile Glu Asp Leu Met Ser
 100 105 110
 Gln His Asn Cys Ser Lys Asp Gly Pro Thr Ser Gln Pro Arg Val Arg
 115 120 125
 Thr Leu Pro Pro Ala Gly Asp Ser Gln Glu Arg Ser Asp Ser Pro Glu
 130 135 140
 Ile Cys His Tyr Glu Lys Ser Phe His Lys His Ser Ala Ala Pro Asn
 145 150 155 160
 Tyr Thr His Cys Gly Leu Phe Gly Asp Pro His Leu Arg Thr Phe Thr
 165 170 175
 Asp His Phe Gln Thr Cys Lys Val Gln Gly Ala Trp Pro Leu Ile Asp
 180 185 190
 Asn Asn Tyr Leu Asn Val Gln Val Thr Asn Thr Pro Val Leu Pro Gly
 195 200 205
 Ser Ala Ala Thr Ala Thr Ser Lys Leu Thr Ile Ile Phe Lys Asn Phe
 210 215 220
 Gln Glu Cys Val Asp Gln Lys Val Tyr Gln Ala Glu Met Asp Glu Leu
 225 230 235 240
 Pro Ser Ala Phe Ala Asp Gly Ser Lys Asn Gly Gly Asp Lys His Gly
 245 250 255
 Ala Asn Ser Leu Lys Ile Thr Glu Lys Val Ser Gly Gln His Val Glu
 260 265 270
 Ile Gln Ala Lys Tyr Ile Gly Thr Thr Ile Val Val Arg Gln Val Gly
 275 280 285
 Arg Tyr Leu Thr Phe Ala Val Arg Met Pro Glu Glu Val Val Asn Ala
 290 295 300
 Val Glu Asp Arg Asp Ser Gln Gly Leu Tyr Leu Cys Leu Arg Gly Cys
 305 310 315 320
 Pro Leu Asn Gln Gln Ile Asp Phe Gln Ala Phe Arg Ala Asn Ala Glu
 325 330 335
 Ser Pro Arg Arg Pro Ala Ala Ala Ser Pro Ser Pro Val Val Pro Glu
 340 345 350
 Thr Phe Pro Tyr Glu Thr Ala Val Ala Lys Cys Lys Glu Lys Leu Pro
 355 360 365
 Val Glu Asp Leu Tyr Tyr Gln Ala Cys Val Phe Asp Leu Leu Thr Thr

JPOXMLDOC01-seq1.app

370					375					380					
Gly 385	Asp	Val	Asn	Phe	Thr 390	Leu	Ala	Ala	Tyr	Tyr 395	Ala	Leu	Glu	Asp	Gly 400
Lys	Met	Leu	His	Ser 405	Asn	Lys	Asp	Lys	Leu 410	His	Leu	Phe	Glu	Arg	Thr
Arg	Glu	Leu	Pro 420	Gly	Ala	Val	Ala	Ala 425	Ala	Ala	Ala	Ala	Ala 430	Thr	Thr
Phe	Pro	Leu 435	Ala	Pro	Gln	Ile	Leu 440	Leu	Gly	Thr	Ile	Pro 445	Leu	Leu	Val
Leu	Leu	Pro	Val	Leu	Trp										
450															

<210> 3
 <211> 449
 <212> PRT
 <213> Rattus norvegicus

<400> 3															
Met 1	Gln	Pro	Pro	Arg 5	Glu	Arg	Leu	Val	Val 10	Thr	Gly	Arg	Ala	Gly 15	Trp
Met	Gly	Met	Gly 20	Arg	Gly	Ala	Gly	Arg 25	Ser	Ala	Leu	Gly	Leu 30	Trp	Pro
Thr	Leu	Ala 35	Phe	Leu	Leu	Cys	Ser 40	Phe	Pro	Ala	Ala	Ile 45	Ser	Pro	Cys
Lys	Ile 50	Leu	Lys	Cys	Asn	Ser 55	Glu	Phe	Trp	Ser	Ala 60	Thr	Ser	Ser	Gly
Ser 65	His	Ala	Pro	Ala	Ser 70	Asp	Asp	Val	Pro	Glu 75	Phe	Cys	Ala	Ala	Leu 80
Arg	Thr	Tyr	Ala	Leu 85	Cys	Thr	Arg	Arg	Thr 90	Ala	Arg	Thr	Cys	Arg 95	Gly
Asp	Leu	Ala	Tyr 100	His	Ser	Ala	Val	His 105	Gly	Ile	Glu	Asp	Leu 110	Met	Ser
Gln	His	Asn 115	Cys	Ser	Lys	Asp	Gly 120	Pro	Thr	Ser	Gln	Pro 125	Arg	Val	Arg
Thr	Leu 130	Pro	Pro	Ala	Gly	Asp 135	Ser	Gln	Glu	Arg	Ser 140	Asp	Ser	Pro	Glu
Ile 145	Cys	His	Tyr	Glu	Lys 150	Ser	Phe	His	Lys	His 155	Ser	Ala	Ala	Pro	Asn 160
Tyr	Thr	His	Cys	Gly 165	Leu	Phe	Gly	Asp	Pro 170	His	Leu	Arg	Thr	Phe 175	Thr
Asp	His	Phe	Gln 180	Thr	Cys	Lys	Val	Gln 185	Gly	Ala	Trp	Pro	Leu 190	Ile	Asp
Asn	Asn	Tyr 195	Leu	Asn	Val	Gln	Val 200	Thr	Asn	Thr	Pro	Val 205	Leu	Pro	Gly
Ser	Ala 210	Ala	Thr	Ala	Thr	Ser 215	Lys	Leu	Thr	Ile	Ile 220	Phe	Lys	Asn	Phe
Gln 225	Glu	Cys	Val	Asp	Gln	Lys	Val	Tyr	Gln	Ala 235	Glu	Met	Asp	Glu	Leu 240
Pro	Ser	Ala	Phe	Ala 245	Asp	Gly	Ser	Lys	Asn 250	Gly	Gly	Asp	Lys	His 255	Gly
Ala	Asn	Ser	Leu 260	Lys	Ile	Thr	Glu	Lys 265	Val	Ser	Gly	Gln	His 270	Val	Glu
Ile	Gln	Ala 275	Lys	Tyr	Ile	Gly	Thr 280	Thr	Ile	Val	Val	Arg 285	Gln	Val	Gly
Arg	Tyr 290	Leu	Thr	Phe	Ala	Val 295	Arg	Met	Pro	Glu	Glu 300	Val	Val	Asn	Ala
Val 305	Glu	Asp	Arg	Asp	Ser 310	Gln	Gly	Leu	Tyr	Leu 315	Cys	Leu	Arg	Gly	Cys 320
Pro	Leu	Asn	Gln	Gln 325	Ile	Asp	Phe	Gln	Ala 330	Phe	Arg	Ala	Asn	Ala 335	Glu
Ser	Pro	Arg	Arg 340	Pro	Ala	Ala	Ala	Ser 345	Pro	Ser	Pro	Val	Val 350	Pro	Glu
Thr	Phe	Pro 355	Tyr	Glu	Thr	Ala	Val 360	Ala	Lys	Cys	Lys	Glu 365	Lys	Leu	Pro
Val	Glu	Asp	Leu	Tyr	Tyr	Gln 375	Ala	Cys	Val	Phe	Asp	Leu	Leu	Thr	Thr
Gly	Asp	Val	Asn	Phe	Thr	Leu	Ala	Ala	Tyr	Tyr	Ala 380	Leu	Glu	Asp	Gly

JPOXMLDOC01-seq1.app

385	Lys	Met	Leu	His	Ser	390	Asn	Lys	Asp	Lys	Leu	395	His	Leu	Phe	Glu	Arg	400	Thr
					405						410						415		
	Arg	Glu	Leu	Pro	Gly	Ala	Val	Ala	Ala	Ala	Ala		Phe	Pro	Leu	Ala	Pro		
				420					425							430			
	Glu	Met	Leu	Pro	Gly	Thr	Val	Thr	Leu	Leu	Val	Leu	Leu	Leu	Pro	Leu	Phe		
			435					440						445					
	Trp																		

<210> 4
 <211> 234
 <212> PRT
 <213> Mus musculus

<400>	4																		
Met	Met	Ser	Ser	Ala	Gln	Phe	Leu	Gly	Leu	Leu	Leu	Leu	Cys	Phe	Gln				
1				5					10					15					
Gly	Thr	Arg	Cys	Asp	Ile	Gln	Met	Thr	Gln	Thr	Thr	Ser	Ser	Leu	Ser				
			20					25					30						
Ala	Ser	Leu	Gly	Asp	Arg	Val	Thr	Ile	Ser	Cys	Arg	Ala	Ser	Gln	Asp				
		35					40					45							
Ile	Ser	Ser	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Lys	Pro	Asp	Gly	Thr	Val				
	50				55						60								
Lys	Leu	Leu	Ile	Tyr	Tyr	Thr	Ser	Arg	Leu	His	Ser	Gly	Val	Pro	Ser				
65				70						75				80					
Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Tyr	Ser	Leu	Thr	Ile	Ser				
				85					90					95					
Asn	Leu	Glu	Gln	Glu	Asp	Ile	Ala	Thr	Tyr	Phe	Cys	Gln	Gln	Leu	Asn				
			100					105					110						
Thr	Leu	Pro	Trp	Thr	Phe	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg					
		115					120												
Ala	Asp	Ala	Ala	Pro	Thr	Val	Ser	Ile	Phe	Pro	Pro	Ser	Ser	Glu	Gln				
	130					135					140								
Leu	Thr	Ser	Gly	Gly	Ala	Ser	Val	Val	Cys	Phe	Leu	Asn	Asn	Phe	Tyr				
145					150				155					160					
Pro	Lys	Asp	Ile	Asn	Val	Lys	Trp	Lys	Ile	Asp	Gly	Ser	Glu	Arg	Gln				
				165					170					175					
Asn	Gly	Val	Leu	Asn	Ser	Trp	Thr	Asp	Gln	Asp	Ser	Lys	Asp	Ser	Thr				
			180					185					190						
Tyr	Ser	Met	Ser	Ser	Thr	Leu	Thr	Leu	Thr	Lys	Asp	Glu	Tyr	Glu	Arg				
		195					200					205							
His	Asn	Ser	Tyr	Thr	Cys	Glu	Ala	Thr	His	Lys	Thr	Ser	Thr	Ser	Pro				
	210					215					220								
Ile	Val	Lys	Ser	Phe	Asn	Arg	Asn	Glu	Cys										
225					230														

<210> 5
 <211> 471
 <212> PRT
 <213> Mus musculus

<400>	5																		
Met	Tyr	Leu	Gly	Leu	Asn	Tyr	Val	Phe	Ile	Val	Phe	Leu	Leu	Asn	Gly				
1				5					10					15					
Val	Gln	Ser	Glu	Val	Lys	Leu	Glu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln				
			20					25					30						
Pro	Gly	Gly	Ser	Met	Lys	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe				
		35					40					45							
Ser	Asp	Ala	Trp	Met	Asp	Trp	Val	Arg	Gln	Ser	Pro	Glu	Lys	Gly	Leu				
	50				55						60								
Glu	Trp	Val	Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr				
65				70					75					80					
Tyr	Ala	Glu	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser				
				85					90					95					
Lys	Arg	Ser	Val	Tyr	Leu	Gln	Met	Asn	Asn	Leu	Arg	Ala	Glu	Asp	Thr				

Gly	Ile	Tyr	100 Tyr	Cys	Thr	Arg	Arg	105 Asp	Gly	Ala	Tyr	Trp	110 Gly	Gln	Gly
Thr	Leu	Val	115 Thr	Val	Ser	Ala	120 Ala	Lys	Thr	Thr	Pro	125 Pro	Ser	Val	Tyr
Pro	Leu	Ala	Pro	Gly	Cys	Gly	135 Asp	Thr	Thr	Gly	140 Ser	Ser	Val	Thr	Leu
145 Gly	Cys	Leu	Val	Lys	Gly	Tyr	Phe	Pro	Glu	155 Ser	Val	Thr	Val	Thr	160 Trp
Asn	Ser	Gly	Ser	Leu	Ser	Ser	Ser	Val	His	Thr	Phe	Pro	Ala	Leu	Leu
Gln	Ser	Gly	Leu	Tyr	Thr	Met	Ser	Ser	Ser	Val	Thr	Val	Pro	Ser	Ser
Thr	Trp	Pro	Ser	Gln	Thr	Val	Thr	Cys	Ser	Val	Ala	His	Pro	Ala	Ser
Ser	Thr	Thr	Val	Asp	Lys	Lys	Leu	Glu	Pro	Ser	Gly	Pro	Ile	Ser	Thr
225 Ile	Asn	Pro	Cys	Pro	Pro	Cys	Lys	Glu	Cys	His	Lys	Cys	Pro	Ala	Pro
Asn	Leu	Glu	Gly	Gly	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Asn	Ile	Lys
Asp	Val	Leu	Met	Ile	Ser	Leu	Thr	Pro	Lys	Val	Thr	Cys	Val	Val	Val
Asp	Val	Ser	Glu	Asp	Asp	Pro	Asp	Val	Gln	Ile	Ser	Trp	Phe	Val	Asn
Asn	Val	Glu	Val	His	Thr	Ala	Gln	Thr	Gln	Thr	His	Arg	Glu	Asp	Tyr
305 Asn	Ser	Thr	Ile	Arg	Val	Val	Ser	Thr	Leu	Pro	Ile	Gln	His	Gln	Asp
Trp	Met	Ser	Gly	Lys	Glu	Phe	Lys	Cys	Lys	Val	Asn	Asn	Lys	Asp	Leu
Pro	Ser	Pro	Ile	Glu	Arg	Thr	Ile	Ser	Lys	Ile	Lys	Gly	Leu	Val	Arg
Ala	Pro	Gln	Val	Tyr	Ile	Leu	Pro	Pro	Pro	Ala	Glu	Gln	Leu	Ser	Arg
Lys	Asp	Val	Ser	Leu	Thr	Cys	Leu	Val	Val	Gly	Phe	Asn	Pro	Gly	Asp
385 Ile	Ser	Val	Glu	Trp	Thr	Ser	Asn	Gly	His	Thr	Glu	Glu	Asn	Tyr	Lys
Asp	Thr	Ala	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Tyr	Phe	Ile	Tyr	Ser
Lys	Leu	Asn	Met	Lys	Thr	Ser	Lys	Trp	Glu	Lys	Thr	Asp	Ser	Phe	Ser
Cys	Asn	Val	Arg	His	Glu	Gly	Leu	Lys	Asn	Tyr	Tyr	Leu	Lys	Lys	Thr
Ile	Ser	Arg	Ser	Pro	Gly	Lys									

<210>	6
<211>	238
<212>	PRT
<213>	Mus musculus

<400>	6															
Met	Lys	Leu	Pro	Val	Arg	Leu	Leu	Val	Leu	Met	Phe	Trp	Ile	Pro	Ala	
1				5					10					15		
Ser	Ser	Ser	Asp	Val	Val	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	Pro	Val	
			20					25					30			
Ser	Leu	Gly	Asp	Gln	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Gln	Ser	Leu	
		35					40					45				
Val	His	Ser	Asn	Gly	Asn	Thr	Tyr	Leu	His	Trp	Tyr	Leu	Gln	Arg	Pro	
	50					55					60					
Gly	Gln	Ser	Pro	Lys	Leu	Leu	Ile	Tyr	Lys	Val	Ser	Asn	Arg	Phe	Ser	
65				70					75					80		
Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	
				85					90					95		
Leu	Lys	Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Leu	Gly	Leu	Tyr	Phe	Cys	

Ser	Gln	Ser	Thr	His	Val	Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu
		100 115					120					125			
Glu	Ile	Lys	Arg	Ala	Asp	Ala	Ala	Pro	Thr	Val	Ser	Ile	Phe	Pro	Pro
		130				135					140				
Ser	Ser	Glu	Gln	Leu	Thr	Ser	Gly	Gly	Ala	Ser	Val	Val	Cys	Phe	Leu
145					150					155					160
Asn	Asn	Phe	Tyr	Pro	Lys	Asp	Ile	Asn	Val	Lys	Trp	Lys	Ile	Asp	Gly
				165					170					175	
Ser	Glu	Arg	Gln	Asn	Gly	Val	Leu	Asn	Ser	Trp	Thr	Asp	Gln	Asp	Ser
			180					185					190		
Lys	Asp	Ser	Thr	Tyr	Ser	Met	Ser	Ser	Thr	Leu	Thr	Leu	Thr	Lys	Asp
		195					200					205			
Glu	Tyr	Glu	Arg	His	Asn	Ser	Tyr	Thr	Cys	Glu	Ala	Thr	His	Lys	Thr
	210					215					220				
Ser	Thr	Ser	Pro	Ile	Val	Lys	Ser	Phe	Asn	Arg	Asn	Glu	Cys		
225					230					235					

<400>	7														
Met 1	Lys	Val	Leu	Ser 5	Leu	Leu	Tyr	Leu	Leu 10	Thr	Ala	Ile	Pro	Gly 15	Ile
Met	Ser	Asp	Val 20	Lys	Leu	Gln	Glu	Ser 25	Gly	Pro	Gly	Leu	Val 30	Lys	Pro
Ser	Gln	Ser 35	Leu	Ser	Leu	Thr	Cys 40	Ser	Val	Thr	Gly	Tyr 45	Ser	Ile	Thr
Thr	Ser 50	Tyr	Tyr	Trp	Asn	Trp 55	Ile	Arg	Gln	Phe	Pro 60	Gly	Asn	Lys	Leu
Glu 65	Trp	Met	Gly	Tyr	Ile 70	Ser	Tyr	Asp	Gly	Thr 75	Asn	Asn	Tyr	Asn	Pro 80
Ser	Leu	Lys	Asn	Arg 85	Ile	Ser	Ile	Thr	Arg 90	Asp	Thr	Ser	Lys	Asn 95	Gln
Phe	Phe	Leu	Arg 100	Leu	Asn	Ser	Val	Thr 105	Thr	Glu	Asp	Thr	Ala 110	Thr	Tyr
Tyr	Cys	Ala 115	Gly	Ser	Phe	Gly	Tyr 120	Ser	Gln	Gly	Thr	Leu 125	Val	Thr	Val
Ser	Ala 130	Ala	Lys	Thr	Thr	Pro 135	Pro	Ser	Val	Tyr	Pro 140	Leu	Ala	Pro	Gly
Cys 145	Gly	Asp	Thr	Thr	Gly 150	Ser	Ser	Val	Thr	Leu 155	Gly	Cys	Leu	Val	Lys 160
Gly	Tyr	Phe	Pro	Glu 165	Ser	Val	Thr	Val	Thr 170	Trp	Asn	Ser	Gly	Ser 175	Leu
Ser	Ser	Ser	Val 180	His	Thr	Phe	Pro	Ala 185	Leu	Leu	Gln	Ser	Gly 190	Leu	Tyr
Thr	Met	Ser 195	Ser	Ser	Val	Thr	Val 200	Pro	Ser	Ser	Thr	Trp 205	Pro	Ser	Gln
Thr	Val 210	Thr	Cys	Ser	Val	Ala 215	His	Pro	Ala	Ser	Ser 220	Thr	Thr	Val	Asp
Lys 225	Lys	Leu	Glu	Pro	Ser 230	Gly	Pro	Ile	Ser	Thr 235	Ile	Asn	Pro	Cys	Pro 240
Pro	Cys	Lys	Glu	Cys 245	His	Lys	Cys	Pro	Ala 250	Pro	Asn	Leu	Glu	Gly 255	Gly
Pro	Ser	Val	Phe 260	Ile	Phe	Pro	Pro	Asn 265	Ile	Lys	Asp	Val	Leu 270	Met	Ile
Ser	Leu	Thr 275	Pro	Lys	Val	Thr	Cys 280	Val	Val	Val	Asp	Val 285	Ser	Glu	Asp
Asp	Pro 290	Asp	Val	Gln	Ile	Ser 295	Trp	Phe	Val	Asn	Asn 300	Val	Glu	Val	His
Thr 305	Ala	Gln	Thr	Gln	Thr 310	His	Arg	Glu	Asp	Tyr 315	Asn	Ser	Thr	Ile	Arg 320
Val	Val	Ser	Thr	Leu 325	Pro	Ile	Gln	His	Gln 330	Asp	Trp	Met	Ser	Gly 335	Lys
Glu	Phe	Lys	Cys	Lys	Val	Asn	Asn	Lys	Asp	Leu	Pro	Ser	Pro	Ile	Glu

JPOXMLDOC01-seq1.app

```

      340      345      350
Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr
      355      360      365
Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu
      370      375      380
Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp
385      390      395
Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val
      400      405      410      415
Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys
      420      425      430
Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His
      435      440      445
Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro
450      455      460
Gly Lys
465

```

<210> 8
 <211> 214
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> chimeric antibody light chain

```

<400> 8
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
1      5      10      15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
      20      25      30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
      35      40      45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50      55      60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65      70      75      80
Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
      85      90      95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100      105      110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115      120      125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130      135      140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145      150      155      160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165      170      175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180      185      190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195      200      205
Phe Asn Arg Gly Glu Cys
210

```

<210> 9
 <211> 446
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> chimeric antibody heavy chain

```

<400> 9
Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

```

JPOXMLDOC01-seq1.app

1	Ser	Met	Lys	Leu	5	Ser	Cys	Ala	Ala	10	Gly	Phe	Thr	Phe	15	Ser	Asp	Ala
				20						25					30			
	Trp	Met	Asp	Trp	Val	Arg	Gln	Ser	Pro	Glu	Lys	Gly	Leu	Glu	Trp	Val		
			35					40						45				
	Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala	Glu		
			50				55					60						
	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Arg	Ser		
65					70						75						80	
	Val	Tyr	Leu	Gln	Met	Asn	Asn	Leu	Arg	Ala	Glu	Asp	Thr	Gly	Ile	Tyr		
				85						90					95			
	Tyr	Cys	Thr	Arg	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val		
				100					105						110			
	Thr	Val	Ser	Ala	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala		
			115					120					125					
	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu		
			130				135					140						
	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly		
145					150						155					160		
	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser		
				165						170					175			
	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu		
				180					185					190				
	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr		
			195					200						205				
	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr		
			210				215					220						
	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe		
225					230						235					240		
	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro		
				245						250					255			
	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val		
				260					265					270				
	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr		
			275					280					285					
	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val		
			290				295					300						
	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys		
305					310						315					320		
	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser		
				325						330					335			
	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro		
				340					345					350				
	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val		
			355					360					365					
	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly		
			370				375					380						
	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp		
385					390						395					400		
	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp		
				405						410					415			
	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His		
				420					425					430				
	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys				
			435					440					445					

<210> 10
 <211> 1461
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Ala Ala Glu Arg Gly Ala Arg Arg Leu Leu Ser Thr Pro Ser Phe
 1 5 10 15
 Trp Leu Tyr Cys Leu Leu Leu Leu Gly Arg Arg Ala Pro Gly Ala Ala
 20 25 30
 Ala Ala Arg Ser Gly Ser Ala Pro Gln Ser Pro Gly Ala Ser Ile Arg

JPOXMLDOC01-seq1.app

		35				40			45						
Thr	Phe	Thr	Pro	Phe	Tyr	Phe	Leu	Val	Glu	Pro	Val	Asp	Thr	Leu	Ser
	50					55					60				
Val	Arg	Gly	Ser	Ser	Val	Ile	Leu	Asn	Cys	Ser	Ala	Tyr	Ser	Glu	Pro
65					70					75					80
Ser	Pro	Lys	Ile	Glu	Trp	Lys	Lys	Asp	Gly	Thr	Phe	Leu	Asn	Leu	Val
				85					90					95	
Ser	Asp	Asp	Arg	Arg	Gln	Leu	Leu	Pro	Asp	Gly	Ser	Leu	Phe	Ile	Ser
			100					105					110		
Asn	Val	Val	His	Ser	Lys	His	Asn	Lys	Pro	Asp	Glu	Gly	Tyr	Tyr	Gln
		115					120					125			
Cys	Val	Ala	Thr	Val	Glu	Ser	Leu	Gly	Thr	Ile	Ile	Ser	Arg	Thr	Ala
	130					135					140				
Lys	Leu	Ile	Val	Ala	Gly	Leu	Pro	Arg	Phe	Thr	Ser	Gln	Pro	Glu	Pro
145					150					155					160
Ser	Ser	Val	Tyr	Ala	Gly	Asn	Asn	Ala	Ile	Leu	Asn	Cys	Glu	Val	Asn
				165					170					175	
Ala	Asp	Leu	Val	Pro	Phe	Val	Arg	Trp	Glu	Gln	Asn	Arg	Gln	Pro	Leu
			180					185					190		
Leu	Leu	Asp	Arg	Val	Ile	Lys	Leu	Pro	Ser	Gly	Met	Leu	Val	Ile	
		195				200					205				
Ser	Asn	Ala	Thr	Glu	Gly	Asp	Gly	Gly	Leu	Tyr	Arg	Cys	Val	Val	Glu
	210					215					220				
Ser	Gly	Gly	Pro	Pro	Lys	Tyr	Ser	Asp	Glu	Val	Glu	Leu	Lys	Val	Leu
225					230					235					240
Pro	Asp	Pro	Glu	Val	Ile	Ser	Asp	Leu	Val	Phe	Leu	Lys	Gln	Pro	Ser
				245					250					255	
Pro	Leu	Val	Arg	Val	Ile	Gly	Gln	Asp	Val	Val	Leu	Pro	Cys	Val	Ala
			260					265					270		
Ser	Gly	Leu	Pro	Thr	Pro	Thr	Ile	Lys	Trp	Met	Lys	Asn	Glu	Glu	Ala
		275					280					285			
Leu	Asp	Thr	Glu	Ser	Ser	Glu	Arg	Leu	Val	Leu	Leu	Ala	Gly	Gly	Ser
	290					295					300				
Leu	Glu	Ile	Ser	Asp	Val	Thr	Glu	Asp	Asp	Ala	Gly	Thr	Tyr	Phe	Cys
305					310					315					320
Ile	Ala	Asp	Asn	Gly	Asn	Glu	Thr	Ile	Glu	Ala	Gln	Ala	Glu	Leu	Thr
				325					330					335	
Val	Gln	Ala	Gln	Pro	Glu	Phe	Leu	Lys	Gln	Pro	Thr	Asn	Ile	Tyr	Ala
			340					345					350		
His	Glu	Ser	Met	Asp	Ile	Val	Phe	Glu	Cys	Glu	Val	Thr	Gly	Lys	Pro
		355					360					365			
Thr	Pro	Thr	Val	Lys	Trp	Val	Lys	Asn	Gly	Asp	Met	Val	Ile	Pro	Ser
					375						380				
Asp	Tyr	Phe	Lys	Ile	Val	Lys	Glu	His	Asn	Leu	Gln	Val	Leu	Gly	Leu
385					390					395					400
Val	Lys	Ser	Asp	Glu	Gly	Phe	Tyr	Gln	Cys	Ile	Ala	Glu	Asn	Asp	Val
				405					410					415	
Gly	Asn	Ala	Gln	Ala	Gly	Ala	Gln	Leu	Ile	Ile	Leu	Glu	His	Ala	Pro
			420					425					430		
Ala	Thr	Thr	Gly	Pro	Leu	Pro	Ser	Ala	Pro	Arg	Asp	Val	Val	Ala	Ser
		435					440					445			
Leu	Val	Ser	Thr	Arg	Phe	Ile	Lys	Leu	Thr	Trp	Arg	Thr	Pro	Ala	Ser
	450					455					460				
Asp	Pro	His	Gly	Asp	Asn	Leu	Thr	Tyr	Ser	Val	Phe	Tyr	Thr	Lys	Glu
465					470					475					480
Gly	Ile	Ala	Arg	Glu	Arg	Val	Glu	Asn	Thr	Ser	His	Pro	Gly	Glu	Met
				485					490					495	
Gln	Val	Thr	Ile	Gln	Asn	Leu	Met	Pro	Ala	Thr	Val	Tyr	Ile	Phe	Arg
			500					505					510		
Val	Met	Ala	Gln	Asn	Lys	His	Gly	Ser	Gly	Glu	Ser	Ser	Ala	Pro	Leu
		515					520					525			
Arg	Val	Glu	Thr	Gln	Pro	Glu	Val	Gln	Leu	Pro	Gly	Pro	Ala	Pro	Asn
	530					535					540				
Leu	Arg	Ala	Tyr	Ala	Ala	Ser	Pro	Thr	Ser	Ile	Thr	Val	Thr	Trp	Glu
545					550					555					560
Thr	Pro	Val	Ser	Gly	Asn	Gly	Glu	Ile	Gln	Asn	Tyr	Lys	Leu	Tyr	Tyr
				565					570					575	
Met	Glu	Lys	Gly	Thr	Asp	Lys	Glu	Gln	Asp	Val	Asp	Val	Ser	Ser	His

JPOXMLDOC01-seq1.app

			580					585					590		
Ser	Tyr	Thr	Ile	Asn	Gly	Leu	Lys	Lys	Tyr	Thr	Glu	Tyr	Ser	Phe	Arg
		595					600					605			
Val	Val	Ala	Tyr	Asn	Lys	His	Gly	Pro	Gly	Val	Ser	Thr	Pro	Asp	Val
		610				615					620				
Ala	Val	Arg	Thr	Leu	Ser	Asp	Val	Pro	Ser	Ala	Ala	Pro	Gln	Asn	Leu
625					630					635				640	
Ser	Leu	Glu	Val	Arg	Asn	Ser	Lys	Ser	Ile	Met	Ile	His	Trp	Gln	Pro
				645					650					655	
Pro	Ala	Pro	Ala	Thr	Gln	Asn	Gly	Gln	Ile	Thr	Gly	Tyr	Lys	Ile	Arg
			660					665					670		
Tyr	Arg	Lys	Ala	Ser	Arg	Lys	Ser	Asp	Val	Thr	Glu	Thr	Leu	Val	Ser
		675					680					685			
Gly	Thr	Gln	Leu	Ser	Gln	Leu	Ile	Glu	Gly	Leu	Asp	Arg	Gly	Thr	Glu
		690				695					700				
Tyr	Asn	Phe	Arg	Val	Ala	Ala	Leu	Thr	Ile	Asn	Gly	Thr	Gly	Pro	Ala
705					710					715					720
Thr	Asp	Trp	Leu	Ser	Ala	Glu	Thr	Phe	Glu	Ser	Asp	Leu	Asp	Glu	Thr
				725					730					735	
Arg	Val	Pro	Glu	Val	Pro	Ser	Ser	Leu	His	Val	Arg	Pro	Leu	Val	Thr
			740					745					750		
Ser	Ile	Val	Val	Ser	Trp	Thr	Pro	Pro	Glu	Asn	Gln	Asn	Ile	Val	Val
		755					760					765			
Arg	Gly	Tyr	Ala	Ile	Gly	Tyr	Gly	Ile	Gly	Ser	Pro	His	Ala	Gln	Thr
		770				775					780				
Ile	Lys	Val	Asp	Tyr	Lys	Gln	Arg	Tyr	Tyr	Thr	Ile	Glu	Asn	Leu	Asp
785					790					795				800	
Pro	Ser	Ser	His	Tyr	Val	Ile	Thr	Leu	Lys	Ala	Phe	Asn	Asn	Val	Gly
				805					810					815	
Glu	Gly	Ile	Pro	Leu	Tyr	Glu	Ser	Ala	Val	Thr	Arg	Pro	His	Thr	Asp
			820					825					830		
Thr	Ser	Glu	Val	Asp	Leu	Phe	Val	Ile	Asn	Ala	Pro	Tyr	Thr	Pro	Val
		835					840					845			
Pro	Asp	Pro	Thr	Pro	Met	Met	Pro	Pro	Val	Gly	Val	Gln	Ala	Ser	Ile
		850				855					860				
Leu	Ser	His	Asp	Thr	Ile	Arg	Ile	Thr	Trp	Ala	Asp	Asn	Ser	Leu	Pro
865					870					875				880	
Lys	His	Gln	Lys	Ile	Thr	Asp	Ser	Arg	Tyr	Thr	Thr	Val	Arg	Trp	Lys
				885					890					895	
Thr	Asn	Ile	Pro	Ala	Asn	Thr	Lys	Tyr	Lys	Asn	Ala	Asn	Ala	Thr	Thr
			900					905					910		
Leu	Ser	Tyr	Leu	Val	Thr	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Tyr	Glu	Phe
		915					920					925			
Ser	Val	Met	Val	Thr	Lys	Gly	Arg	Arg	Ser	Ser	Thr	Trp	Ser	Met	Thr
		930				93									

JPOXMLDOC01-seq1.app

1115	Arg	Thr	Thr	Ser	His	1120	Gln	Lys	Lys	Lys	Arg	1125	Ala	Cys	Lys
1130	Ser	Val	Asn	Gly	Ser	1135	Lys	Tyr	Lys	Gly	Asn	1140	Ser	Lys	Asp
1145	Lys	Pro	Pro	Asp	Leu	1150	Ile	His	His	Glu	Arg	1155	Leu	Glu	Leu
1160	Pro	Ile	Asp	Lys	Ser	1165	Asp	Pro	Asn	Pro	Ile	1170	Met	Thr	Asp
1175	Pro	Ile	Pro	Arg	Asn	1180	Gln	Asp	Ile	Thr	Pro	1185	Val	Asp	Asn
1190	Met	Asp	Ser	Asn	Ile	1195	Gln	Arg	Arg	Asn	Ser	1200	Tyr	Arg	Gly
1205	Glu	Ser	Glu	Asp	Ser	1210	Ser	Thr	Leu	Ala	Gly	1215	Arg	Arg	Gly
1220	Arg	Pro	Lys	Met	Met	1225	Pro	Phe	Asp	Ser	Gln	1230	Pro	Pro	Gln
1235	Val	Ile	Ser	Ala	His	1240	Ile	His	Ser	Leu	Asp	1245	Asn	Pro	His
1250	His	Phe	His	Ser	Ser	1255	Leu	Ala	Ser	Pro	Ala	1260	Arg	Ser	His
1265	Tyr	His	Pro	Gly	Ser	1270	Trp	Pro	Ile	Gly	Thr	1275	Ser	Met	Ser
1280	Ser	Asp	Arg	Ala	Asn	1285	Thr	Glu	Ser	Val	Arg	1290	Asn	Thr	Pro
1295	Thr	Asp	Thr	Met	Pro	1300	Ser	Ser	Ser	Gln	Thr	1305	Cys	Cys	Thr
1310	His	Gln	Asp	Pro	Glu	1315	Ala	Thr	Ser	Ser	Ser	1320	Tyr	Leu	Ala
1325	Ser	Gln	Glu	Glu	Asp	1330	Gly	Gln	Ser	Leu	Pro	1335	Thr	Ala	His
1340	Arg	Pro	Ser	His	Pro	1345	Lys	Ser	Phe	Ala	Val	1350	Pro	Ala	Ile
1355	Pro	Pro	Gly	Pro	Pro	1360	Tyr	Asp	Pro	Ala	Leu	1365	Pro	Ser	Thr
1370	Leu	Leu	Ser	Gln	Gln	1375	Leu	Asn	His	His	Ile	1380	His	Ser	Val
1385	Thr	Ala	Ser	Ile	Gly	1390	Leu	Gly	Arg	Ser	Arg	1395	Pro	Pro	Met
1400	Val	Val	Val	Pro	Ser	1405	Pro	Glu	Val	Gln	Glu	1410	Thr	Thr	Arg
1415	Leu	Glu	Asp	Ser	Glu	1420	Ser	Tyr	Glu	Pro	Asp	1425	Glu	Leu	Thr
1430	Glu	Met	Ala	His	Leu	1435	Gly	Leu	Met	Lys	Asp	1440	Leu	Asn	Ala
1445	Thr	Thr	Ala			1450						1455			
1460															

<210> 11
 <211> 446
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody heavy chain HA

<400> 11
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Ala
 20 25 30
 Trp Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu
 50 55 60
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile
 65 70 75 80

JPOXMLDOC01-seq1.app

Ala	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Leu	Tyr
				85					90					95	
Tyr	Cys	Thr	Arg	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Lys	Gly	Thr	Thr	Val
			100					105					110		
Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala
		115					120					125			
Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu
	130					135				140					
Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly
145					150					155					160
Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser
				165					170					175	
Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu
			180					185					190		
Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr
		195					200					205			
Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr
	210					215					220				
Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe
225					230					235					240
Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro
				245					250					255	
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val
			260					265					270		
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr
		275					280					285			
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val
	290					295					300				
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys
305					310					315					320
Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser
				325					330					335	
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro
			340					345					350		
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val
		355					360					365			
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly
	370					375					380				
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp
385					390					395					400
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp
				405					410					415	
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His
			420					425					430		
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
		435					440					445			

<210> 12
 <211> 446
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody heavy chain HB

<400>	12														
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Arg
1			5					10					15		
Ser	Leu	Arg	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Ala
			20					25					30		
Trp	Met	Asp	Trp	Phe	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala	Glu
	50					55				60					
Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Ile
65					70					75					80
Val	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Thr	Glu	Asp	Thr	Ala	Leu	Tyr

JPOXMLDOC01-seq1.app

				85				90					95		
Tyr	Cys	Thr	Arg	100	Asp	Gly	Ala	105	Trp	Gly	Lys	Gly	110	Thr	Val
Thr	Val	Ser	Ser	115	Ala	Ser	Thr	120	Lys	Gly	Pro	Ser	125	Phe	Pro
Pro	Ser	Ser	Lys	130	Ser	Thr	Ser	135	Gly	Gly	Thr	Ala	140	Leu	Gly
Val	Lys	Asp	Tyr	145	Phe	Pro	Glu	150	Val	Thr	Val	Ser	155	Trp	Asn
Ala	Leu	Thr	Ser	160	Gly	Val	His	165	Thr	Phe	Pro	Ala	170	Val	Gln
Gly	Leu	Tyr	Ser	175	Leu	Ser	Ser	180	Val	Val	Thr	Val	185	Pro	Ser
Gly	Thr	Gln	Thr	190	Tyr	Ile	Cys	195	Val	Asn	His	Lys	200	Pro	Ser
Lys	Val	Asp	Lys	205	Lys	Val	Glu	210	Pro	Lys	Ser	Cys	215	Asp	Lys
Cys	Pro	Pro	Cys	220	Pro	Ala	Pro	225	Glu	Leu	Leu	Gly	230	Gly	Pro
Leu	Phe	Pro	Pro	235	Lys	Pro	Lys	240	Asp	Thr	Leu	Met	245	Ile	Ser
Glu	Val	Thr	Cys	250	Val	Val	Val	255	Asp	Val	Ser	His	260	Glu	Asp
Lys	Phe	Asn	Trp	265	Tyr	Val	Asp	270	Gly	Val	Glu	Val	275	His	Asn
Lys	Pro	Arg	Glu	280	Glu	Gln	Tyr	285	Asn	Ser	Thr	Tyr	290	Arg	Val
Leu	Thr	Val	Leu	295	His	Gln	Asp	300	Trp	Leu	Asn	Gly	305	Lys	Glu
Lys	Val	Ser	Asn	310	Lys	Ala	Leu	315	Pro	Ala	Pro	Ile	320	Glu	Lys
Lys	Ala	Lys	Gly	325	Gln	Pro	Arg	330	Gln	Val	Tyr	Thr	335	Leu	Thr
Ser	Arg	Asp	Glu	340	Leu	Thr	Lys	345	Asn	Gln	Val	Ser	350	Leu	Thr
Lys	Gly	Phe	Tyr	355	Pro	Ser	Asp	360	Ile	Ala	Val	Glu	365	Glu	Ser
Gln	Pro	Glu	Asn	370	Asn	Tyr	Lys	375	Thr	Thr	Pro	Pro	380	Val	Leu
Gly	Ser	Phe	Phe	385	Leu	Tyr	Ser	390	Lys	Leu	Thr	Val	395	Asp	Lys
Gln	Gln	Gly	Asn	400	Val	Phe	Ser	405	Cys	Ser	Val	Met	410	His	Glu
Asn	His	Tyr	Thr	415	Gln	Lys	Ser	420	Leu	Ser	Leu	Ser	425	Pro	Gly
				430				435					440		445

<210> 13
 <211> 446
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody heavy chain HC

<400>	13														
Glu	Val	Gln	Leu	5	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly
1															15
Ser	Leu	Arg	Leu	20	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp
															30
Trp	Met	Asp	Trp	35	Phe	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp
															45
Ala	Glu	Ile	Arg	50	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala
															60
Ser	Val	Lys	Gly	65	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser
															80
Val	Tyr	Leu	Gln	85	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Leu
															95

JPOXMLDOC01-seq1.app

Tyr	Cys	Thr	Arg	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Lys	Gly	Thr	Thr	Val
			100					105					110		
Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala
		115					120					125			
Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu
	130					135					140				
Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly
145					150					155					160
Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser
				165					170					175	
Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu
			180					185					190		
Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr
		195					200					205			
Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr
	210					215					220				
Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe
225					230					235					240
Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro
				245					250					255	
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val
			260					265					270		
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr
		275					280					285			
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val
	290					295					300				
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys
305					310					315					320
Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser
				325					330					335	
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro
			340					345					350		
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val
		355					360					365			
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly
	370					375					380				
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp
385					390					395					400
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp
				405					410					415	
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His
			420					425					430		
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
		435					440					445			

<210> 14
 <211> 446
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody heavy chain HD

<400>	14														
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Arg
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Ala
		20						25					30		
Trp	Met	Asp	Trp	Phe	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala	Glu
	50					55					60				
Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Ile
65					70					75					80
Ala	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Thr	Glu	Asp	Thr	Ala	Leu	Tyr
				85					90					95	
Tyr	Cys	Thr	Arg	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Lys	Gly	Thr	Thr	Val

JPOXMLDOC01-seq1.app

Thr	Val	Ser	100	Ser	Ala	Ser	Thr	Lys	105	Gly	Pro	Ser	Val	Phe	110	Pro	Leu	Ala
Pro	Ser	115	Ser	Lys	Ser	Thr	Ser	120	Gly	Gly	Thr	Ala	Ala	125	Leu	Gly	Cys	Leu
Val	130	Lys	Asp	Tyr	Phe	Pro	135	Glu	Pro	Val	Thr	Val	140	Ser	Trp	Asn	Ser	Gly
Ala	Leu	Thr	Ser	Gly	165	Val	His	Thr	Phe	Pro	170	Ala	Val	Leu	Gln	Ser	175	Ser
Gly	Leu	Tyr	Ser	180	Leu	Ser	Ser	Val	Val	185	Thr	Val	Pro	Ser	Ser	190	Ser	Leu
Gly	Thr	Gln	195	Thr	Tyr	Ile	Cys	Asn	200	Val	Asn	His	Lys	Pro	205	Ser	Asn	Thr
Lys	Val	210	Asp	Lys	Lys	Val	Glu	215	Pro	Lys	Ser	Cys	Asp	220	Lys	Thr	His	Thr
Cys	225	Pro	Pro	Cys	Pro	Ala	230	Pro	Glu	Leu	Leu	Gly	235	Gly	Pro	Ser	Val	Phe
Leu	Phe	Pro	Pro	Lys	245	Pro	Lys	Asp	Thr	Leu	250	Met	Ile	Ser	Arg	Thr	255	Pro
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	265	Ser	His	Glu	Asp	Pro	270	Glu	Val	
Lys	Phe	Asn	275	Trp	Tyr	Val	Asp	Gly	280	Val	Glu	Val	His	Asn	285	Ala	Lys	Thr
Lys	Pro	290	Arg	Glu	Glu	Gln	Tyr	295	Asn	Ser	Thr	Tyr	Arg	300	Val	Val	Ser	Val
Leu	Thr	Val	Leu	His	Gln	310	Asp	Trp	Leu	Asn	Gly	315	Lys	Glu	Tyr	Lys	Cys	320
Lys	Val	Ser	Asn	Lys	325	Ala	Leu	Pro	Ala	Pro	330	Ile	Glu	Lys	Thr	Ile	Ser	
Lys	Ala	Lys	Gly	340	Gln	Pro	Arg	Glu	Pro	345	Gln	Val	Tyr	Thr	Leu	350	Pro	Pro
Ser	Arg	Asp	355	Glu	Leu	Thr	Lys	Asn	360	Gln	Val	Ser	Leu	Thr	365	Cys	Leu	Val
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	375	Ile	Ala	Val	Glu	Trp	380	Glu	Ser	Asn	Gly	
Gln	385	Pro	Glu	Asn	Asn	Tyr	390	Lys	Thr	Thr	Pro	Pro	395	Val	Leu	Asp	Ser	Asp
Gly	Ser	Phe	Phe	Leu	405	Tyr	Ser	Lys	Leu	Thr	410	Val	Asp	Lys	Ser	Arg	Trp	
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	425	Val	Met	His	Glu	Ala	430	Leu	His	
Asn	His	Tyr	435	Thr	Gln	Lys	Ser	Leu	440	Ser	Leu	Ser	Pro	Gly	445	Lys		

<210>	15
<211>	446
<212>	PRT
<213>	Artificial Sequence

<220>
<223> humanized antibody heavy chain HE

<400>	15															
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Arg	
1				5					10					15		
Ser	Leu	Arg	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Ala	
			20					25					30			
Trp	Met	Asp	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
		35					40					45				
Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala	Glu	
	50					55					60					
Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Ile	
65					70					75					80	
Val	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Thr	Glu	Asp	Thr	Ala	Leu	Tyr	
			85						90					95		
Tyr	Cys	Thr	Arg	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Lys	Gly	Thr	Thr	Val	
			100					105					110			

JPOXMLDOC01-seq1.app

Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala
		115					120					125			
Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu
	130					135					140				
Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly
145					150					155					160
Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser
				165					170					175	
Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu
			180					185					190		
Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr
		195					200					205			
Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr
	210					215					220				
Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe
225					230					235					240
Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro
				245					250					255	
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val
			260					265					270		
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr
		275					280					285			
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val
	290					295					300				
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys
305					310					315					320
Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser
				325					330					335	
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro
			340					345					350		
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val
		355					360					365			
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly
	370					375					380				
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp
385					390					395					400
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp
				405					410					415	
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His
			420					425					430		
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
		435					440					445			

<210> 16

<211> 446

<212> PRT

<213> Artificial Sequence

<220>

<223> humanized antibody heavy chain HF

<400> 16

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Arg
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Ala
			20					25					30		
Trp	Met	Asp	Trp	Phe	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala	Glu
	50					55					60				
Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Ile
65					70					75				80	
Ala	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Val	Tyr
				85					90					95	
Tyr	Cys	Thr	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Lys	Gly	Thr	Thr	Val	
			100				105					110			
Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala

JPOXMLDOC01-seq1.app

Pro	Ser	115	Lys	Ser	Thr	Ser	120	Gly	Gly	Thr	Ala	Ala	125	Leu	Gly	Cys	Leu
Val	130	Lys	Asp	Tyr	Phe	Pro	135	Glu	Pro	Val	Thr	Val	140	Ser	Trp	Asn	Ser
145	Ala	Leu	Thr	Ser	Gly	150	Val	His	Thr	Phe	Pro	155	Ala	Val	Leu	Gln	Ser
Gly	Leu	Tyr	Ser	165	Leu	Ser	Ser	Val	Val	170	Thr	Val	Pro	Ser	Ser	175	Leu
Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	185	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	
Lys	Val	195	Asp	Lys	Lys	Val	Glu	200	Pro	Lys	Ser	Cys	Asp	205	Lys	Thr	His
Cys	210	Pro	Pro	Cys	Pro	Ala	215	Pro	Glu	Leu	Leu	Gly	220	Gly	Pro	Ser	Val
225	Leu	Phe	Pro	Pro	Lys	230	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro
Glu	Val	Thr	Cys	245	Val	Val	Val	Asp	Val	250	Ser	His	Glu	Asp	Pro	Glu	Val
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	265	Val	Glu	Val	His	Asn	270	Ala	Lys	Thr
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	280	Asn	Ser	Thr	Tyr	Arg	Val	285	Val	Val	Ser
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	320	
Lys	Val	Ser	Asn	Lys	310	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	335	
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	350	
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	365	
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	380	
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	400	
Gln	Gln	Gly	Asn	405	Val	Phe	Ser	Cys	Ser	410	Val	Met	His	Glu	Ala	Leu	His
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	425	430		
		435					440					445					

<210> 17
 <211> 446
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody heavy chain HG

<400>	17																
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Arg		
1			5					10					15				
Ser	Leu	Arg	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Ala		
			20					25					30				
Trp	Met	Asp	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val		
		35					40					45					
Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala	Glu		
		50				55				60							
Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Ile		
65					70				75						80		
Ala	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Leu	Tyr		
			85						90								
Tyr	Cys	Thr	Arg	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Lys	Gly	Thr	Thr	Val		
			100					105					110				
Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala		
		115					120					125					

JPOXMLDOC01-seq1.app

Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu
Val	130	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser
145						150				155					Gly
Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser
				165					170					175	
Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu
			180					185					190		
Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr
		195					200					205			
Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr
	210					215					220				
Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe
225					230					235					240
Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro
				245					250					255	
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val
			260					265					270		
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr
		275					280					285			
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val
	290					295					300				
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys
305					310					315					320
Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser
				325					330					335	
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro
			340					345					350		
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val
		355					360					365			
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly
	370					375					380				
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp
385					390					395					400
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp
				405					410					415	
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His
			420					425					430		
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
		435					440					445			

<210> 18
 <211> 446
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody heavy chain HH

<400>	18														
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Arg
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Ala
			20					25					30		
Trp	Met	Asp	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ala	Glu	Ile	Arg	Ser	Lys	Ala	Asn	Asn	His	Ala	Thr	Tyr	Tyr	Ala	Glu
	50					55				60					
Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Ser	Lys	Ser	Ile	
65					70					75				80	
Ala	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Val	Tyr
				85					90				95		
Tyr	Cys	Thr	Arg	Arg	Asp	Gly	Ala	Tyr	Trp	Gly	Lys	Gly	Thr	Thr	Val
			100					105					110		
Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala
			115				120					125			
Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu

JPOXMLDOC01-seq1.app

Val	130	Lys	Asp	Tyr	Phe	Pro	135	Glu	Pro	Val	Thr	Val	140	Ser	Trp	Asn	Ser	Gly
145	Ala	Leu	Thr	Ser	Gly	150	Val	His	Thr	Phe	Pro	155	Ala	Val	Leu	Gln	Ser	160
				165	Leu	Ser	Ser	Val	Val	170	Thr	Val	Pro	Ser	Ser	175	Ser	Leu
Gly	Thr	Gln	180	Thr	Tyr	Ile	Cys	Asn	185	Val	Asn	His	Lys	Pro	190	Ser	Asn	Thr
		195	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr		
Lys	210	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe		
Cys	225	Phe	Pro	Pro	Lys	230	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	240	Pro
				245	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	255	
Glu	Val	Thr	Cys	260	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	270	
Lys	Phe	Asn	275	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	285	
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	295	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	300	
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	320		
305	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	335	
				325	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	350	
Lys	Ala	Lys	Gly	340	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	350	
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val			
		355	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly		
Lys	Gly	370	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly		
Gln	Pro	Glu	Asn	Asn	Tyr	390	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	400	
385	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	415	
			405	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His			
Gln	Gln	Gly	Asn	420	Gln	Lys	Ser	Leu	Ser	Pro	Gly	Lys						
Asn	His	Tyr	435	Thr	Gln	Lys	Ser	Leu	Ser	Pro	Gly	Lys						
								440					445					

<210> 19
 <211> 214
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody light chain KA

<400>	19	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Val	Ser	Ala	Ser	Val	Gly
1					5					10						15	
Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Asp	Ile	Ser	Ser	Tyr		
		20						25					30				
Leu	Asn	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile		
		35					40					45					
Tyr	Tyr	Thr	Ser	Arg	Leu	His	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly		
		50				55					60						
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro		
65					70					75					80		
Glu	Asp	Phe	Ala	Ser	Tyr	Phe	Cys	Gln	Gln	Leu	Asn	Thr	Leu	Pro	Trp		
				85					90					95			
Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Met	Glu	Arg	Thr	Val	Ala	Ala		
		100						105					110				
Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly		
		115					120					125					
Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala		
		130				135						140					

JPOXMLDOC01-seq1.app

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> 20
 <211> 214
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody light chain KB

<400> 20
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Ser Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Met Glu Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> 21
 <211> 214
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody light chain KC

<400> 21
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

JPOXMLDOC01-seq1.app

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Ser Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Met Glu Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210

<210> 22
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> humanized antibody light chain KD

<400> 22
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Met Glu Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210

<210> 23
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> humanized antibody light chain KE

```

<400> 23
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Val Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Ser Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Met Glu Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210

```

```

<210> 24
<211> 214
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> humanized antibody light chain KF

```

```

<400> 24
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Val Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Met Glu Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys

```

210

<210> 25
 <211> 214
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized antibody light chain KG

<400> 25
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Thr Lys Val Glu Met Glu Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> 26
 <211> 14
 <212> PRT
 <213> Mus musculus

<400> 26

Glu Glu Val Val Asn Ala Val Glu Asp Trp Asp Ser Gln Gly
 1 5 10

<210> 27
 <211> 14
 <212> PRT
 <213> Mus musculus

<400> 27

Asn Gln Gln Ile Asp Phe Gln Ala Phe His Thr Asn Ala Glu
 1 5 10

<210> 28
 <211> 11
 <212> PRT
 <213> Mus musculus

<400> 28

Pro	Thr	Ala	Pro	Glu	Thr	Phe	Pro	Tyr	Glu	Thr
1				5					10	

<210> 29

<211> 11

<212> PRT

<213> Mus musculus

<400> 29

Lys	Leu	Pro	Val	Glu	Asp	Leu	Tyr	Tyr	Gln	Ala
1				5					10	

<210> 30

<211> 11

<212> PRT

<213> Mus musculus

<400> 30

Arg	Ala	Ser	Gln	Asp	Ile	Ser	Ser	Tyr	Leu	Asn
1				5					10	

<210> 31

<211> 7

<212> PRT

<213> Mus musculus

<400> 31

Tyr	Thr	Ser	Arg	Leu	His	Ser
1				5		

<210> 32

<211> 7

<212> PRT

<213> Mus musculus

<400> 32

Gln	Gln	Leu	Asn	Thr	Leu	Pro
1				5		

<210> 33

<211> 5

<212> PRT

<213> Mus musculus

<400> 33

Asp	Ala	Trp	Met	Asp
1				5

<210> 34

<211> 19

<212> PRT

<213> Mus musculus

<400> 34

Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser
1 5 10 15

Val Lys Gly

<210> 35
<211> 5
<212> PRT
<213> Mus musculus

<400> 35

Arg Asp Gly Ala Tyr
1 5

<210> 36
<211> 16
<212> PRT
<213> Mus musculus

<400> 36

Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His
1 5 10 15

<210> 37
<211> 7
<212> PRT
<213> Mus musculus

<400> 37

Lys Val Ser Asn Arg Phe Ser
1 5

<210> 38
<211> 7
<212> PRT
<213> Mus musculus

<400> 38

Ser Gln Ser Thr His Val Pro
1 5

<210> 39
<211> 6
<212> PRT
<213> Mus musculus

<400> 39

Thr Ser Tyr Tyr Trp Asn
1 5

<210> 40
<211> 16
<212> PRT
<213> Mus musculus

<400> 40

Tyr Ile Ser Tyr Asp Gly Thr Asn Asn Tyr Asn Pro Ser Leu Lys Asn
 1 5 10 15

<210> 41

<211> 116

<212> PRT

<213> Artificial Sequence

<220>

<223> humanized antibody heavy chain

<400> 41

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Ala
 20 25 30
 Trp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Glu Ile Arg Ser Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu
 50 55 60
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile
 65 70 75 80
 Val Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr
 85 90 95
 Tyr Cys Thr Arg Arg Asp Gly Ala Tyr Trp Gly Lys Gly Thr Thr Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 42

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> humanized antibody light chain

<400> 42

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Ser Tyr Phe Cys Gln Gln Leu Asn Thr Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Met Glu
 100 105

<210> 43

<211> 348

<212> DNA

<213> Artificial Sequence

<220>

<223> a gene encoding humanized antibody heavy chain

<400> 43

JPOXMLDOC01-seq1.app

gaagtgcagc	tggtggaatc	tggcggcgga	ctggtgcagc	ctggcagatc	cctgagactg	60
tcctgtaccg	cctccgggctt	caccttctcc	gacgcctgga	tggattgggt	gcgacaggct	120
cctggcaagg	gcctggaatg	ggtggccgag	atccgggtcca	aggccaacaa	ccacgccacc	180
tactacgccg	agtctgtgaa	gggccgggttc	accatctccc	gggacgactc	caagtccatc	240
gtgtacctgc	agatgaactc	cctgcggacc	gaggacaccg	ccctgtacta	ctgcaccaga	300
agggacggcg	cctactgggg	caagggcacc	acagtgcag	tgtcctcc		348

<210> 44
 <211> 321
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> a gene encoding humanized antibody light chain

<400> 44	
gacatccaga	tgacccagtc cccctcctcc gtgtctgctt ccgtgggcga cagagtgacc 60
atcacctgtc	gggcctccca ggacatctcc tcctacctga actggtatca gcagaagccc 120
ggcaaggccc	ccaagctgct gatctactac acctcccggc tgcactccgg cgtgccctct 180
agattttccg	gctctggctc cggcaccgac tttaccctga ccatctccag cctgcagccc 240
gaggacttcg	cctcctactt ctgtcagcag ctgaacaccc tgccctggac ctttggcgga 300
ggcaccaagg	tggaatgga a 321

<210> 45
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> PLP139-151

<400> 45	
His Ser Leu Gly Lys Trp Leu Gly His Pro Asp Lys Phe	
1 5 10	

<210> 46
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> spacer

<400> 46	
Ser Gly Ser Gly	
1	